

CURRICULUM VITAE

Name: Emile Eugene Voest
Work Address: Medical Director, Executive Board of Directors, Netherlands Cancer Institute,
Plesmanlaan 121, 1066 CX, The Netherlands.

Date of birth: August 20, 1959

Place of birth: Utrecht, The Netherlands

Social status: Married, 3 daughters

Education:

1971-1977 Gymnasium, Zeist
1978 Chemistry, Utrecht University, The Netherlands
1978-1985 Utrecht University School of Medicine; Utrecht, The Netherlands
1985 MD Utrecht University School of Medicine; Utrecht, The Netherlands
1993 PhD University of Utrecht, The Netherlands (cum laude)
Dissertation: *"Iron chelation, Oxygen radicals, and Anthracyclines in the Treatment of Cancer"*

Postdoctoral Training:

Internships and Residencies:

1985-1986 Surgical Internship, Hofpoort Hospital, Woerden, The Netherlands
1986-1988 Internal Medicine & Cardiology Internship, Oudenrijn Hospital, Utrecht, The Netherlands
1988-1990 Internal Medicine Resident, Diaconessenhuis Utrecht, The Netherlands
1991-1993 Internal Medicine Resident, University Hospital Utrecht, Utrecht, The Netherlands

Clinical and Research Fellowships:

1990-1991 Research Fellow in Oncology, University Hospital Utrecht, Utrecht, The Netherlands (Prof. Dr. J.J.M. Marx)
1993-1994 Clinical Fellow in Oncology, University Hospital Utrecht, Utrecht, The Netherlands (Prof. Dr. G.H. Blijham)
1994-1996 Research Fellow of the Dutch Cancer Society, Amsterdam, The Netherlands:
1994-1995 Research Fellow, Department of Surgical Research, Children's Hospital, Harvard Medical School, Boston, MA.
(Dr. J. Folkman): Angiogenesis
01/1995-04/1995 Netherlands Cancer Institute, Amsterdam, The Netherlands (Prof. Dr. S. Rodenhuis): High dose chemotherapy and stem cell transplant
05/1995-12/1995 University Hospital Utrecht, Utrecht, The Netherlands (Prof. Dr. C.J. Lips): Hereditary cancers

Visiting scientist

04/2011-11/2011 University California San Diego, CA: Bioinformatics (Dr. K. Frazer) and systems biology (Dr. T. Ideker)

Current Positions:

1999- Professor of Medical Oncology, University of Utrecht, University Medical Center, Utrecht
2010- Chair of the Scientific Advisory Board of InterNA
2013- Editorial board of Clinical Cancer Research
2014- Medical Director, Executive Board of Directors, Netherlands Cancer Institute
2014- Board member of the Center for Personalized Cancer Treatment
2014- Board member of Biomed NKI AVL
2014- Board member of AVL foundation
2014- Board member of Biotherapeutics Unit (AmBTU)
2014- Supervisory Board member Netherlands Laboratory or Anticancer Drug Formulation
2015- Editorial board of JAMA Oncology
2015- Member of supervisory board Hartwig Medical Foundation
2016- Editorial Board ESMO Open, Cancer Horizons
2016- Executive Board member Cancer Core Europe
2019- Member of the Council of the European Society for Medical Oncology (ESMO)
2019- Chair of the ESMO Publishing Committee
2019- Senior Group Leader of the Oncode Institute
2019- Advisor of Agalia Venture Capital

Past Positions:

1994-1995 Fellowship Dutch Cancer Society
1996-1998 Staff member department of Medical Oncology, University Hospital Utrecht, The Netherlands
1996-2003 Head of the Laboratory of Medical Oncology, University Hospital Utrecht
1998-1999 Acting head of the department of Medical Oncology, University Medical Center Utrecht
1998-2004 Member of the Internal Medicine Steering Committee
1999-2005 Co-director of the research institute "Developmental biology and Oncology", University Medical Center, Utrecht
1999-2014 Head Department of Medical Oncology
1999-2002 Editorial board of "Kanker", journal of the Dutch Cancer Society
1999-2005 Co-director of Research Institute "Genes" at the University Medical Center
2000-2008 Chair Scientific Evaluation Committee for Individual Grants University Medical Center Utrecht
2000-2004 Member of the scientific committee of the Dutch Internal Medicine Conference

2001 Editor of "Tumor angiogenesis and microcirculation", MDI Publishers New York

2001-2005 Board member of the Royal Academy of Sciences Graduate School of Developmental Biology

2001-2006 Board Member Graduate School of Developmental Biology

2002-2006 Member of the commission to stimulate research of the Comprehensive Cancer Center Central Netherlands

2002-2006 Member of the Scientific Advisory Board of "Primagen" (2002-2006)

2002-2008 Member of the Committee of Clinical Applied Research of the Dutch Cancer Society

2002-2010 Member of the Scientific Advisory Board of the "Vanderes Foundation"

2005-2010 Director of the Oncology Research Program UMC Utrecht

2005-2006 Member of the Scientific Advisory Board of ABN Amro Life Sciences Capital

2005-2010 Member of the Scientific Advisory Board of Forbion Capital

2005-2011 Member of the Committee of Translational Research of the Dutch Cancer Society

2006-2010 Chair of the Oncology Research Program of the UMC Utrecht

2006-2010 Member of the Academic Biomedical Cluster Committee "High potentials"

2006-2011 Editor of the "Angiogenese Journaal"

2007-2009 Board Member of the Graduate School of Life Sciences

2007-2010 Director of Cancer Research Program of the UMC Utrecht Cancer Center

2007-2013 Board member of the Dutch Working Party on Immunology-Oncology

2007-2012 Member of the scientific committee of the Dutch/Belgian Medical Oncology Conference

2008-2011 Member of the Scientific Board of the Dutch Cancer Society

2009-2011 Chairman of the yearly course "Angiogenesis: a key target in oncology"

2010-2013 Founder and Director of PhD program "Clinical and Translational Oncology" of the Graduate School of Life Sciences

2011-2014 Chair of the Scientific Advisory Board of the Dutch Cancer Society

2011 Member Educational Committee ASCO

2011 Member Educational Committee AACR

2011-2013 Manager Research and Education, Division of Internal Medicine and Dermatology, UMC Utrecht.

2012-2014 Chair of the Scientific Advisory Board of the Pediatric Oncology Foundation "KiKa"

2012-2013 Chair CRC ASCO subcommittee "Meaningful endpoints of clinical trials"

2013-2014 Medical Manager Medical Oncology Disciplines, UMC Utrecht in preparation of merger with NKI.

2013 Co-chair of the joint scientific advisory board of SU2C-AACR and SU2C-KWF

2010-2014 Founder and chair of the Center for Personalized Cancer Treatment

2008-2015 Member of the scientific advisory board of Targeted Anti-tumor Therapy Congress

2012-2017 Member of the Cancer Research Committee (CRC) American Society of Clinical Oncology (ASCO)

2013-2016 Medical Director of the Hub Foundation for Organoid Technology (established September 26, 2013).

2015-2016 Chair ASCO Cancer Research Committee

2017	Member Scientific Program Committee of the EACR-OECI Conference on Precision Medicine for Cancer (March 2017)
2017	Scientific Chair of ESMO Asia (November 2017)
2016-2018	Chair Audit Committee and Treasurer ESMO
2015-2018	Member of the Executive Board of the European Society for Medical Oncology (ESMO)
2015-2019	Member of the Scientific Audit Committee of the EORTC

Member of various advisory boards of biotechnology and pharmaceutical companies

Certifications:

1985 The Netherlands M.D. License Registration
 1993 Dutch Board of Internal Medicine Certification
 1996 Board Certification as Medical Oncologist

Memberships:

American Association for Cancer Research
 Dutch Association for Oncology
 Dutch Association for Medical Oncology
 European Society for Medical Oncology
 Dutch Association for Internal Medicine

Spin-outs

Founder and CSO of ***PIFA Therapeutics***, a company based on platinum induced fatty acids as a tool to prevent resistance to anti-cancer therapies. The company was founded Feb 9, 2011 and terminated 2014.

Good Clinical Practice training

2006 2-day GCP course UMC Utrecht
 2008 NIH certificate
 2011 BROK certificate
 2013 Basic Life Support certificate
 2016 BROK re-certification

Dissertations

1. Bottone, A.E. Doxorubicin and cardiac contractile function.
 02-02-1999
 Jongasma, H.J., Beer, E.L.de., Voest, E.E.
2. Los, M. The Von Hippel-Lindau gene and its role in angiogenesis & renal cell carcinoma.
 20-09-2002

- Voest,E.E., Gebbink,M.F.B.G.
3. Reijneveld,J.C. Adhesion and angiogenesis in central nervous system tumours.
25-04-2003
Voest,E.E., Gijn,J.van Taphoorn,M.J.B.
 4. Drixler,T.A. Aspects of anti-angiogenic treatment; experimental studies on the effect of inhibition of angiogenesis in colorectal liver metastases, retinopathy of prematurity, and liver regeneration.
12-06-2003
Borel Rinkes,I.H.M., Voest,E.E.
 5. Velde,E.A.te Surgery and (anti)angiogenesis.
20-06-2003
Borel Rinkes,I.H.M. Voest,E.E.
 6. Reijerkerk,A. Plasminogen Activation in Cancer.
27-01-2004
Voest,E.E. Gebbink,M.F.B.G
 7. Vogten,J.M. Angiogenesis in the liver.
16-04-2004
Borel Rinkes,I.H.M. Voest,E.E.
 8. Beerepoot,L.V. Early clinical evaluation of antivasular drugs for cancer treatment.
28-05-2004
Voest,E.E. Gebbink, M.F.B.G
 9. Bloemendal,H.J. Human antibodies in cancer treatment
22-09-2004
Voest,E.E. Logtenberg,T., Boer,H.C.de, Gebbink,M.F.B.G.
 10. Koop, E.A. Receptor Protein Tyrosine Phosphatase μ in vascular function
30-09-2005
Voest E.E., Gebbink M.F.B.G.
 11. Brandsma, D. Adhesion in leptomeningeal metastases. Towards early diagnosis and treatment
07-12-2005
Voest EE, Taphoorn M.
 12. Lolkema, M.P. Hypoxia Inducible Factor independent functions for the von Hippel-Lindau tumor suppressor gene
07-02-2006
Voest EE, Giles R.
 13. Teunissen, S. In palliative cancer care symptoms mean everything
06-02-2007
Voest EE, de Haes JCJM, de Graeff A

14. Mehra, N. Novel biomarkers for cancer detection and prognostication
23-03-2007
Voest EE
15. Mans, D. Novel functions of the von Hippel-Lindau tumor suppressor
08-04-2008
Voest EE, Giles R
16. van Rooijen, E Genetic analysis of the ciliary protein Lrrc50 and the von Hippel Lindau tumor suppressor in zebrafish
08-12-2009
Voest EE, Clevers H, Giles R, Schulte-Merker S
17. Wessels, H. Needs and preferences of cancer patients
23-11-2009
Voest EE, A. de Graeff
18. Langenberg, M. The role of endothelial cells in tumor angiogenesis translated to clinical relevance
12-04-2010
Voest EE, Schellens J, Witteveen PO
19. Devriese, L.A. Pharmacokinetics of novel anticancer drugs and dynamics of circulating tumor cells in early clinical studies
30-11-2011
Schellens J, Voest EE
20. Roodhart, J. Understanding the tumor host interaction: the key to more effective anti-cancer treatment
19-04-2012
Voest EE
21. Vermaat, J Novel approaches in prognosis and personalized treatment of cancer
10-05-2012
Voest EE
22. Snoeren, N. Colorectal liver metastases; factors affecting outcome after surgery
02-05-2013
Borel Rinkes I, van Hillegersberg R, Voest EE
23. Basten, S Functional aspects of cilia and tumor suppressor genes
21-05-2103
Giles RH, Voest EE
24. Daenen, L Host mediated mechanisms of resistance to antitumor therapies
18-04-2013
Voest EE
25. Shaltiel, I Phosphoregulation in the reversal of DNA Damage checkpoints

- 24-09-2014
Medema RH, Voest EE
26. Hoogstraat, M On the heterogeneity of tumor sequencing
30-10-2014
Cuppen E, Voest EE
27. Houthuijzen, J Lipid signalling in anti-cancer drug resistance
12-04-2016
Voest EE
28. Cirkel, G Strategies to overcome anti-neoplastic drug resistance
27-10-2016
M.P.J. Lolkema, Voest EE,
29. Ooft, S
30. Weeber, F Predicting treatment outcome by DNA and organoids
21-12-2017
Voest EE
31. Bijlsma, RM Unsolicited genetic findings in clinical oncology
09-01-2019
Voest EE, Breedenoord A
32. Dijkstra, K
33. van der Velden, D Strategies to implement and execute precision oncology
06-12-2018
Voest EE
34. Seinstra, D Revealing the role of tumor heterogeneity and plasticity in breast cancer
22-12-2018
Van Rheenen J, Voest EE
35. Wouters, R Ethics of Personalized Oncology
08-01-2019
Breedenoord A, Voest EE
36. Stangl, C
37. Chalabi, M
38. Cattaneo, C
39. Van der Haar, J
40. Hoes, L

41. L. Schipper
42. M. Van Bergen-Henegouwen
43. H. Van der Wijngaart

Patents

Inventor on five unique patents (see attachment).

Research Projects and Funding:

Is anthracycline-induced cardiomyopathy caused by a direct interaction of anthracyclines with the contractile proteins?

(Grant of the Dutch Heart Foundation, NHS 93.074),

Thesis "Doxorubicin and cardiac contractile function" by A. Bottone (02-02-1999)

Oncogenetics and Angiogenesis

Grant of the University Hospital Utrecht, The Netherlands, 1995-2000

Antiangiogenic gene therapy of intracerebral tumors

Grant of the Dutch Organisation of Scientific Research, NWO 920-03-075

Development of Antiangiogenic gene therapy

Grant of the Faculty of Medicine, University of Utrecht, 1996-1999

Intraocular antiangiogenic gene therapy

Grant of the Fischer Foundation, 1996-2000

The role of angiogenesis in colorectal tumors and wounding

Grant of the Department of Surgery, University Hospital Utrecht, 1996-2001

Grant of the "Gastrostart" Foundation

The angiogenic profile of von Hippel-Lindau disease

Grant of the Dutch Organisation of Scientific Research, NWO 920-03-024, 1997-2000

Discovery of specific targets on tumor endothelium by phage display of recombinant antibodies

Grant of the Vanderes Foundation, 1997-1999

Grant of Ubisys, 1999

The role of carboxypeptidases in angiogenesis and tumor growth

Grant of the Dutch Cancer Society, UU 99-2114, 1999-2003

Functional analysis of the von Hippel-Lindau tumor suppressor gene using conditional gene disruption

Grant of the Dutch Cancer Society, UU 99-1879, 1999-2003

Surrogate endpoints to determine biological activity of angiogenesis inhibitors in early clinical trials

Grant of the Dutch Organisation of Scientific Research NWO 920-03-090, 2000-2003

The role of the von Hippel Lindau tumor suppressor gene in the development of renal cell cancer

Grant of the Dutch Organisation of Scientific Research NWO, 2001-2004

Evaluation of immuno-modulatory effects of anti-angiogenic therapies

Grant of the Dutch Organisation of Scientific Research NWO 920-03-179, 2001-2004

Circulating endothelial cells as a pharmacodynamic endpoint

Grant of Primagen Inc, Amsterdam, The Netherlands, 2002-2005

The zebrafish as a model to study the function of the von Hippel Lindau tumor suppressor gene

Grant of the Vanderes Foundation, 2004-2006

Oncologische Zorgvernieuwing

Grant IKMN 2005-2007 (25.000 euro)

Hoe geven patiënten zorg en behandeling vorm als ze niet gehinderd worden door bestaande medische kaders en niet gestuurd worden door de logistiek en organisatie binnen een ziekenhuis?

Grant RVVZ 2005-2007 (100.000 euro)

Circulating biomarkers as a pharmacodynamic endpoint

Grant Primagen 2005-2008

Research grant to investigate bevacizumab functions

Grant Roche 2005-2009

Functional analysis of the von Hippel-Lindau tumor suppressor gene in the zebrafish

Grant of the Dutch Cancer Society, UU 2006-3565, 2006-2010

Chemokine receptor inhibition as a targeted molecular anti cancer approach

Grant of the Vanderes Foundation 2006-2008

Plasma mitochondrial nucleic acids as predictors of response to chemotherapy and survival

Prof Dr EE Voest

UU 2007-4526, 2007-2009

Crossing the barrier: from intravenous to effective oral formulations of chemotherapy

Prof J Schellens, Prof J Beijnen, Prof EE Voest

ZonMW 95100101 2009

Bone marrow progenitor cell mediated host repair response as a mechanism of resistance to chemotherapy.

Prof EE Voest

ZonMW 92003550, 2010

Mesenchymal progenitor cell-mediated resistance to chemotherapy

Prof EE Voest

Dutch Cancer Society, UU 2009-4534

Chemotherapy-induced tumor progression via host-mediated, VEGFR-dependent mechanisms

Prof EE Voest

ZonMW 92003559, 2010

Center for Personalized Cancer Care

Prof EE Voest, Prof E. Cuppen

Dutch Cancer Society, HUBR 2011-4880

A Randomized Two arm Phase III Study in Patients Post Radical Resection of Liver Metastasis of Colorectal Cancer to Investigate Bevacizumab (q3w) in Combination With Capecitabine Plus Oxaliplatin (CAPOX) (q3w) as vs CAPOX (q3w) alone as Adjuvant Treatment.

Principal Investigators: Prof R Hillegersberg and Prof EE Voest

Dutch Cancer Society, CKTO 2006-12

A randomized phase II study to explore the efficacy and feasibility of upfront bi-monthly rotations between Everolimus and Pazopanib with sequential treatment of first line Pazopanib and second line Everolimus until progression in patients with advanced or metastatic clear cell renal cancer.

Principal Investigators: Prof EE Voest, Prof S Sleijfer, Prof J Haanen.

Dutch Cancer Society, UU 2011-5236

DNA guided personalized cancer treatment

Principal investigators: Prof EE Voest and Prof R Bernards, on behalf of the Center for Personalized Cancer Treatment.

Stand up to Cancer (SU2C) 2012-2017

Platinum-induced fatty acids (PIFAs) as mediators of chemoresistance in cancer patients.

Principal investigators: Prof EE Voest

Dutch Cancer Society UU 2012-5712

Genotyping of male breast cancer

Principal investigators: Prof P van Diest, Prof E Cuppen, Prof EE Voest

Dutch Cancer Society UU 2012-5637

The functional relevance of fusion genes to colorectal cancer: a gateway to novel treatment opportunities?

Principal investigators: Dr. M. Koudijs, Dr. W. Kloosterman, Prof EE Voest

Dutch Cancer Society UU 2012-5710

Gravitation Grant "Cancer Genomics Center"

Dutch Organisation of Scientific Research NWO 2012-2022

Principal Investigator Prof R Bernards, co-applicant Prof Dr EE Voest

Dynamic response assessments to combat drug resistance in cancer

Principal Investigators Prof EE Voest and Prof R Bernards on behalf of the Center for Personalized Cancer Treatment

Josephine Nefkens Foundation 2013

Increased quality of care by more efficient use of drugs in oncology.

Principal Investigators Prof EE Voest and Dr J Martens on behalf of the Center for Personalized Cancer Treatment

CZ (Health Care Organisation) 2014

Prediction of treatment outcome in patients with metastatic breast cancer by in vitro drug testing using individual patient-derived tumor organoids.

Principal Investigators Prof EE Voest and Prof H Clevers.

Pink Ribbon 2014-2018

Exploring the use of lung organoids in personalized medicine

Principal investigators Prof H Clevers, Prof EE Voest, Prof H Bos

Dutch Cancer Society HUBR 2014-7006

An empirical ethics study to introduce next-generation DNA sequencing into cancer care in a responsible way

Principal investigators" Dr A. Bredenoord and Prof EE Voest

UU 2014-6800

COLOSYS: A systems approach to preventing drug resistance in colon cancer

Principal investigators NKI: Prof dr L. Wessels and Prof dr EE Voest

ZonMW/ ERACoSysMed 2016- 9003035005

Dynamic response assessments to understand responses to immunotherapy in metastatic cancer

Principal Investigators Prof EE Voest, Prof T Schumacher, Prof J Haanen and Prof R Bernards on behalf of the Center for Personalized Cancer Treatment

Josephine Nefkens Foundation 2016

The Drug Rediscovery Protocol (DRUP trial)

Principal Investigators Prof EE Voest, Prof AJ Gelderblom en Prof H Verheul

Dutch Cancer Society NKI 2016-1/10014

Targeting SHP2 in Pancreatic Cancer. The Lustgarten Foundation together with Stand up to Cancer and AACR. Principal Investigators Prof R Bernards, Prof H Agul and Prof EE Voest. 2018-2020 1M for preclinical research followed by a 3 M grant for the clinical translation.

International Publications

D.L. van der Velden, H. van der Wijngaart, L.R. Hoes, J.M. van Berge Henegouwen, E. van Werkhoven, P. Roepman, R.L. Schilsky, W.W.J. de Leng, A.D.R. Huitema, B. Nuijen, P.M. Nederlof, C.M.L. van Herpen, D.J.A. de Groot, L.A. Devriese, A. Hoeben, M.J.A. de Jonge, M. Chalabi, E.F. Smit, A.J. de Langen, N. Mehra, M. Labots, E. Kapiteijn, S. Sleijfer, E. Cuppen, H.M.W. Verheul, H. Gelderblom, **E.E. Voest**. Drug rediscovery protocol: expanded use of existing anti-cancer drugs. *Nature* under review

Danielle Seinstra, Lennart Kester, Daphne van der Velden, Marlous Hoogstraat, Iris Nederlof, Annelot van Rossum, Esther H. Lips, Sabine Linn, Lodewyk Wessels, Hugo M. Horlings, Jelle Wesseling, **Emile Voest**, Alexander van Oudenaarden, Jacco van Rheenen. Single-cell dissection of intra-tumoral heterogeneity reveals new information on therapy response and progression free survival of breast cancer patients. submitted

- **2019**

Salgado R, Solit DB, Rimm DL, Bogaerts J, Canetta R, Lively T, Lyerly K, Span PN, Bateman-House A, Makady A, Bergmann L, Nagai S, Smith C, Robson M, Savage M, **Voest E**, Sweeney C, Lambin P, Thomas M, Harris L, Lacombe D, Massard C; IBCD-Faculty. Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. *Eur J Cancer*; 2019 May 3

van Waalwijk van Doorn-Khosrovani SB, Pisters-van Roy A, van Saase L, van der Graaff M, Gijzen J, Sleijfer S, Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, van der Velden DL, van Werkhoven E, Retel VP, van Harten WH, Huitema ADR, Timmers L, Gelderblom H, Verheul HMW, **Voest EE**. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. *Ann Oncol*. 2019; April

Daphne L. van der Velden, Laura A. Levit, JD, George J. Chang, Matthew A. Facktor, Karyn A. Goodman, Jeffrey Kaufman, Gottfried E. Konecny, Sharon W. Kwan, Margaret Mooney, Grace Smith, Stephen B. Solomon, Alda Tam, David Michael Waterhouse, **Emile E. Voest**, When Oncologic Treatment Options Outpace the Existing Evidence: Contributing Factors and a Path Forward A Joint Statement by the American College of Surgeons Commission on Cancer, American Society for Radiation Oncology, American Society of Clinical Oncology, Society of Interventional Radiology, and Society of Surgical Oncology. *Journal of Cancer Policy*, 2019

Joris van de Haar, Louisa Hoes, **Emile Voest**. Advancing molecular tumour boards: highly needed to maximise the impact of precision medicine. *ESMO Open* 2019

van de Haar, J., Canisius, S., Yu, M.K., **Voest, E.E.**, Wessels, L.F.A., Ideker, T. Identifying epistasis in cancer genomes: a delicate affair. *Cell*, 2019 in press

Wouter Scheper, Sander Kelderman, Lorenzo Fanchi, Carsten Linnemann, Gavin Bendle, Marije de Rooij, Christian Hirt, Maarten Slagter, Krijn Dijkstra, Roel Kluin, Petur Snaebjornsson, Brad Nelson, Henry Zijlmans, Gemma Kenter, **Emile Voest**, John B.A.G. Haanen, and Ton N. Schumacher. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. *Nature Medicine* 2019;25(1):89-94

Norman Sachs, Dominique D. Zomer-van Ommen, Angelos Papaspyropoulos, Inha Heo, Lena Böttinger, Dymph Klay, Fleur Weeber, Guizela Huelsz-Prince, Nino Iakobachvili, Marco C. Viveen, Anna Lyubimova, Luc Teeven, Sepideh Derakhshan, Jeroen Korving, Harry Begthel, Kuldeep Kumawat, Emilio Ramos, Matthijs F.M. van Oosterhout, Eduardo P. Olimpio, Joep de Ligt, Krijn K. Dijkstra, Egbert F. Smit, Maarten van der Linden, **Emile E. Voest**, Coline H.M. van Moorsel, Cornelis K. van der Ent, Edwin Cuppen, Alexander van Oudenaarden, Frank E. Coenjaerts, Linde Meyaard, Louis J. Bont, Peter J. Peters, Sander J. Tans, Jeroen S. van Zon, Sylvia F. Boj, Robert G. Vries, Jeffrey M. Beekman, Hans Clevers
Long-term expanding human airway organoids for disease modelling. *EMBO J*, 2019 in press

- **2018**

Krijn K. Dijkstra, Chiara M. Cattaneo, Fleur Weeber, Myriam Chalabi, Joris van de Haar, Lorenzo Fanchi, Maarten Slagter, Daphne L. van der Velden, Sovann Kaing, Sander Kelderman, Nienke van Rooij, Monique E. van Leerdam, Annekatrien Depla, Egbert Smit, Koen Hartemink, Rosa Groot, Monika Wolkers, Norman Sachs, Petur Snaebjornsson, Kim Monkhorst, John Haanen, Hans Clevers, Ton N. Schumacher, **Emile E. Voest**
Facilitating individualized T cell therapy by co-culture of peripheral blood lymphocytes and tumor organoids. *Cell* 2018, 174(6):1586-1598

Fabien Calvo, Giovanni Apolone, Michael Baumann, Carlos Caldas, Julio E. Celis, Francesco de Lorenzo, Ingemar Ernberg, Ulrik Ringborg, John Rowell, Josep Tabernero, **Emile Voest**, Alexander Eggermont. Cancer Core Europe: a European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century. *Eur J Cancer* 2018; 103:155-159

Pam K. Mangat, Susan Halabi, Suanna S. Bruinooge, Elizabeth Garrett-Mayer, Ajjai Alva, Katherine A. Janeway, Philip J. Stella, **Emile Voest**, Kathleen J. Yost, Jane Perlmutter, Navin Pinto, Edward S. Kim, Richard L. Schilsky. Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. *JCO Precision Oncology*, 2018

van der Velden DL, Houthuijzen JM, Roodhart JML, van Werkhoven E, **Voest EE**. Detection of endogenously circulating Mesenchymal Stem Cells in human cancer patients. *Int J Cancer* 2018; 143(10):2516-2524

van der Velden DL, Cirkel GA, Houthuijzen JM, van Werkhoven E, Roodhart JML, Daenen LGM, Kaing S, Gerrits J, Verhoeven-Duif NM, Grootsholten C, Boot H, Sessa C, Bloemendal HJ, De Vos FY, **Voest EE**. Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids. *Cancer Chemother Pharmacol*. 2018; 81(5):911-921

Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, **Voest E**, Zon R, Francisco M, Green S, Sherwood S, Harvey RD, Schilsky RL. American Society of Clinical Oncology Statement: Biosimilars in Oncology. *J Clin Oncol*. 2018; 36(12):1260-1265

Ellen van Rooijen, Glenn van de Hoek, Ive Logister, Henry Ajzenberg, Nine V. Knoers, Freek van Eeden, **Emile E. Voest**, Stefan Schulte-Merker and Rachel H. Giles. The von Hippel-

Lindau gene is required to maintain renal proximal tubule and glomerulus integrity in zebrafish larvae. *Nephron* 2018; 138(4):310-323

R.M. Bijlsma, R. Wouters, H. Wessels-Wynia, A. May, M. Aussems, **E.E. Voest**, A. Bredenoord. Managing unsolicited findings in genomics: a qualitative interview study with cancer patients. *Psycho-oncology* 2018; 27(4):1327-1333

Norman Sachs, Joep de Ligt, Ewa Gogola, Gergana Bounova, Anjali Balgobind, Fleur Weeber, Karin Wind, Ana Gracanin, Harry Begthel, Jeroen Korving, Ruben van Boxtel, Alexandra A. Duarte, Daphne Lelieveld, Robert Ernst, Francis Blokzijl, Ies Nijman, Marlous Hoogstraat, Marieke van de Ven, David A. Egan, Sylvia Boj, **Emile E. Voest**, Lodewyk Wessels, Paul J. van Diest, Sven Rottenberg, Robert Vries, Edwin Cuppen, and Hans Clevers. A living biobank of breast cancer organoids captures disease heterogeneity. *Cell* 2018; 172(1-2):373-386

Maudy Walraven, Marjolein Y.V. Homs, Astrid A.M. van der Veldt, Henk Dekker, Jose Koldenhof, Richard Honeywell, Arjan Barendrecht, Silvie A.E. Sebastian, **Emile E. Voest**, Mark Roest, Henk M.W. Verheul. Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab. *Angiogenesis*, 2018; 21(2):325-334

Bijlsma RM, Wessels H, Wouters RHP, May AM, Aussems MGEM, **Voest EE**, Bredenoord AL. Cancer patients' intentions towards receiving unsolicited genetic information obtained using next-generation sequencing. *Fam Cancer*. 2018; Apr;17(2):309-316

- **2017**

Roel H.P. Wouters, Rhodé M. Bijlsma, Geert W.J. Frederix, Margreet G.E.M. Aussems, Johannes J.M.vanDelden, **Emile E.Voest**, and Annelien L.Bredenoord. Is It Our Duty To Hunt for Pathogenic Mutations? *Trends in Molecular Medicine*, 2017 S1471-4914(17)30212-5.

D.L. van der Velden¹, C.M.L. van Herpen², H.W.M. van Laarhoven³, E.F. Smit⁴, H.J.M. Groen⁵, S.M. Willems⁶, P.M. Nederlof⁷, M.H.G. Langenberg⁸, E. Cuppen⁹, S. Sleijfer¹⁰, N. Steeghs¹¹, **E.E. Voest**. Molecular tumor boards: current practice and future needs *Annals of Oncology* 2017, 28(12):3070-3075

Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, **Voest E**, Douillard JY, McGregor K, Ciardiello F. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. *ESMO Open*. 2017 Jan 16;1(6):e000142.

Hendriks JJMA, Haanen JBAG, **Voest EE**, Schellens JHM, Huitema ADR, Beijnen JH. Fixed Dosing of Monoclonal Antibodies in Oncology. *The Oncologist*. 2017, 22(10):1212-1221

Meulendijks D, Jacob W, **Voest EE**, Mau-Sørensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema M, Langenberg MH, de Jonge MJA, Sleijfer S, Han JY, Calles A, Felipe E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Harring SV, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M,

Lassen U. Phase Ib study of lumretuzumab plus cetuximab or erlotinib in solid tumor patients and evaluation of HER3 and heregulin as potential biomarkers of clinical activity. *Clin Cancer Res.* 2017; 23(18):5406-5415

Stephen Leong, Rebecca A. Moss, Daniel W. Bowles, Joseph Ware, Jing Zhou, Jill M. Spoerke, Mark R. Lackner, Geetha Shankar, Jennifer Schutzman, Ruud van der Noll, **Emile E. Voest**, Jan H.M. Schellens. A Phase I Dose-Escalation Study of the Safety and pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors. *The Oncologist*, 2017; 22(12):1491-1499.

Fabrice André , Dr. Alexander S. Baras , Dr. José Baselga , Dr. Phillipe L. Bedard , Michael F. Berger , Mariska Bierkens , Dr. Fabien Calvo , Dr. Debyani Chakravarty , Kristen K. Dang , Dr. Nancy E. Davidson , Catherine Del Vecchio Fitz , Semih Dogan , Dr. Raymond N. DuBois , Mr. Matthew Ducar , Dr. P. Andrew Futreal , Dr. Jianjiong Gao , Francisco Garcia , Stu Gardos, Dr. Christopher D. Gocke , Benjamin E. Gross , Justin Guinney , Zachary J. Heins , Stephanie Hintzen , Dr. Hugo Horlings , Jan Hudeček , Dr. David M. Hyman , Dr. Suzanne Kamel-Reid , Cyriac Kandoth , Walter Kinyua , Priti Kumari , Ritika Kundra , Marc Ladanyi , Dr. Céline Lefèbvre , Michele L. LeNoue-Newton , Eva Lepisto , Dr. Mia A. Levy , Dr. Neal I. Lindeman , James Lindsay , Dr. David Liu , Zhibin Lu , Dr. Laura E. MacConaill , Ian Maurer , Dr. David Maxwell , Mr. Gerrit A. Meijer , Funda Meric-Bersntam , Dr. Christine M. Micheel , Clinton Miller , Dr. Gordon B. Mills , Nathanael D. Moore , Dr. Petra M. Nederlof , Larsson Omberg , John A. Orechia , Ben Ho Park , Dr. Trevor J. Pugh , Mr. Brendan Reardon , Dr. Barrett J. Rollins , Dr. Mark J. Routbort , Dr. Charles L. Sawyers , Deboarh Schrag , Dr. Nikolaus Schultz , Kenna Shaw , Priyanka Shivdasani , Dr. Lillian L. Siu , David B. Solit , Dr. Gabe S. Sonke , Dr. Jean-Charles Soria , Parin Sripakdeevong , Natalie Stickle , Dr. Thomas Stricker , Shawn M. Sweeney , Barry S. Taylor , Mr. Jelle ten Hoeve , Stacy B. Thomas , Laura J. Vant 't Veer , Mr. Tony van de Velde , Dr. Harm Van Tinteren , Dr. Victor E. Velculescu , Dr. Carl Virtanen , Dr. **Emile E. Voest** , Lucy L. Wang , Dr. Chetna Wathoo , Stuart Watt , Ms. Celeste Yu , Thomas V. Yu , Emily Yu , Dr. Ahmet Zehir , Mr. Hongxin Zhang. AACR Project GENIE: Powering Precision Medicine Through An International Consortium *Cancer Discovery* 2017; 7(8):818-831

D.J. Vis^{1*}, J Lewin^{2*}, R.G. Liao³, M. Mao⁴, F. Andre⁵, R.L. Ward⁶, F. Calvo⁷, B.T. Teh⁸, A.A. Camargo⁹, B.M. Knoppers¹⁰, C. Sawyers¹¹, L.F.A. Wessels^{1,12}, M. Lawler^{13**}, L.L. Siu^{2**}, **E. Voest**^{1**} on behalf of the Clinical Working Group of the Global Alliance for Genomics and Health. Towards a Global Cancer Knowledge Network: Dissecting the current international cancer genomic sequencing landscape. *Annals of Oncology*, 2017; 28(5):1145-1151

Beerling E, Oosterom I, **Voest E**, Lolkema M, van Rheenen J. Intravital characterization of tumor cell migration in pancreatic cancer. *Intravital*. 2016 Nov 18;5(3):e1261773

F. Weeber, S. Ooft, K. Dijkstra, **E. Voest**. Tumor organoids as a pre-clinical cancer model for drug discovery. *Cell Chemical Biology*, 2017; 24(9):1092-1100

Houthuijzen JM, Oosterom I, Hudson BD, Hirasawa A, Daenen LG, McLean CM, Hansen SV, van Jaarsveld MT, Peeper DS, Jafari Sadatmand S, Roodhart JM, van de Lest CH, Ulven T, Ishihara K, Milligan G, **Voest EE**. Fatty acid 16:4(n-3) stimulates a GPR120-induced signaling cascade in splenic macrophages to promote chemotherapy resistance. *FASEB J.* 2017;31(5):2195-2209

Fleur Weeber, Geert A Cirkel, Marlous Hoogstraat, Sander Bins, Christa G.M Gadellaa - van Hooijdonk, Salo Ooft, Erik v Werkhoven, Stefan M Willems, Marijn van Stralen, Wouter B Veldhuis, Nicolle J.M. Besselink, Hugo M Horlings, Neeltje Steeghs, Maja de Jonge, Marlies H.G Langenberg, Lodewyk Wessels, Edwin P.J.G Cuppen, JHM Schellens, Stefan Sleijfer, Martijn Lolkema, **Emile E Voest**. Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study. *Oncotarget* 2017, 8(33):55582-55592

Wigard P. Kloosterman^{1,#,*}, Robert R.J. Coebergh van den Braak^{2,#}, Mark Pieterse^{1,#}, Markus J. van Roosmalen^{1,#}, Anieta M. Sieuwerts^{3,#}, Christina Stangl¹, Ronne Brunekreef¹, Zarina S. Lalmahomed², Salo Ooft⁴, Anne van Galen³, Marcel Smid³, Armel Lefebvre¹, Fried Zwartkruis⁵, John W.M. Martens³, John A. Foekens³, Katharina Biermann⁶, Marco J. Koudijs¹, Jan N.M. IJzermans^{2,\$}, **Emile E. Voest**^{4,\$} A systematic analysis of oncogenic gene fusions in primary colon cancers. *Cancer Research* 2017, 77(14):3814-3822

Snoeren N, van Hillegersberg R, Schouten SB, Bergman AM, van Werkhoven E, Dalesio O, Tollenaar RA, Verheul HM, van der Sijp J, Borel Rinkes IH, **Voest EE**; Hepatica study group. Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study. *Neoplasia*. 2017 Jan 12;19(2):93-99.

Bins S, Cirkel GA, Gadellaa-van Hooijdonk CG, Weeber F, Nijman IJ, Bruggink AH, van Diest PJ, Willems SM, Veldhuis WB, van den Heuvel MM, de Knecht RJ, Koudijs MJ, van Werkhoven E, Mathijssen RH, Cuppen E, Sleijfer S, Schellens JH, **Voest EE**, Langenberg MH, de Jonge MJ, Steeghs N, Lolkema MP. Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies. *The Oncologist*. 2017 Jan;22(1):33-40

Cirkel GA, Hamberg P, Sleijfer S, Loosveld OJ, Dercksen MW, Los M, Polee MB, van den Berkmortel F, Aarts MJ, Beerepoot LV, Groenewegen G, Lolkema MP, Tascilar M, Portielje JE, Peters FP, Klümpen HJ, van der Noort V, Haanen JB, **Voest EE**; Dutch WIN-O Consortium. Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial. *JAMA Oncol*. 2017;3(4):501-508

- **2016**

Josep Tabernero, Malvika Vyas, Rosa Giuliani, Dirk Arnold, Fatima Cardoso, Paolo G Casali, Andres Cervantes, Alexander MM Eggermont, Alexandru Eniu, Jacek Jassem, George Pentheroudakis, Solange Peters, Stefan Rauh, Christoph C Zielinski, Rolf A Stahel, **Emile Voest**, Jean-Yves Douillard, Keith McGregor, Fortunato Ciardello. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. *ESMO Open* 2016;1:e000142.

Christian Dittrich, Michael Kosty, Svetlana Jezdic, Doug Pyle, Rossana Berardi, Jonas Bergh, Nagi El-Saghir, Jean-Pierre Lotz, Pia Österlund, Nicholas Pavlidis, Gunta Purkalne, Ahmad Awada, Susana Banerjee, Smita Bhatia, Jan Bogaerts, Jan Buckner, Fatima Cardoso, Paolo Casali, Edward Chu, Julia Lee Close, Bertrand Coiffier, Roisin Connolly, Sarah Coupland, Luigi De Petris, Maria De Santis, Elisabeth G E de Vries, Don S Dizon, Jennifer Duff, Linda R Duska, Alexandru Eniu, Marc Ernstoff, Enriqueta Felip, Martin F Fey, Jill Gilbert, Nicolas

Girard, Andor W J M Glaudemans, Priya K Gopalan, Axel Grothey, Stephen M Hahn, Diana Hanna, Christian Herold, Jørn Herrstedt, Krisztian Homicsko, Dennie V Jones, Lorenz Jost, Ulrich Keilholz, Saad Khan, Alexander Kiss, Claus-Henning Köhne, Rainer Kunstfeld, Heinz-Josef Lenz, Stuart Lichtman, Lisa Licitra, Thomas Lion, Saskia Litière, Lifang Liu, Patrick J Loehrer, Merry Jennifer Markham, Ben Markman, Marius Mayerhoefer, Johannes G Meran, Olivier Michielin, Elizabeth Charlotte Moser, Giannis Mountzios, Timothy Moynihan, Torsten Nielsen, Yuichiro Ohe, Kjell Öberg, Antonio Palumbo, Fedro Alessandro Peccatori, Michael Pfeilstöcker, Chandrajit Raut, Scot C Remick, Mark Robson, Piotr Rutkowski, Roberto Salgado, Lidia Schapira, Eva Schernhammer, Martin Schlumberger, Hans-Joachim Schmoll, Lowell Schnipper, Cristiana Sessa, Charles L Shapiro, Julie Steele, Cora N Sternberg, Friedrich Stiefel, Florian Strasser, Roger Stupp, Richard Sullivan, Josep Tabernero, Luzia Travado, Marcel Verheij, **Emile Voest**, Everett Vokes, Jamie Von Roenn, Jeffrey S Weber, Hans Wildiers, Yosef Yarden. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. *ESMO Open* 2016;1(5):e0000970

Roel H.P. Wouters , Rhodé M. Bijlsma, Margreet G.E.M. Ausems, Johannes J.M. van Delden, **Emile E. Voest**, Annelien L. Bredenoord. Am I my family's keeper? Disclosure dilemmas in next generation DNA sequencing. *Hum Mutations* 2016, 37:1257-1262

Kemper K, Krijgsman O, Kong X, Cornelissen-Steijger P, Shahrabi A, Weeber F, van der Velden DL, Bleijerveld OB, Kuilman T, Kluin RJ, Sun C, **Voest EE**, Ju YS, Schumacher TN, Altelaar AF, McDermott U, Adams DJ, Blank CU, Haanen JB, Peeper DS. BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. *Cell Rep.* 2016; S2211-1247(16)30662-3.

Lillian L. Siu, Mark Lawler, David Haussler, Bartha Maria Knoppers, Jeremy Lewin, Daniel J. Vis, Rachel Liao, Fabrice Andre, Ian Banks, J. Carl Barrett, Carlos Caldas, Anamaria Aranha Camargo, Rebecca C. Fitzgerald, Mao Mao, John E. Mattison, William Pao, William R. Sellers, Patrick Sullivan, Bin Tean Teh, Robyn Ward, Jean Claude ZenKlusen, Charles L Sawyers, **Emile E. Voest**. Facilitating a culture of responsible and effective sharing of cancer genome data. *Nature Medicine*, 22(5):464-471, 2016

Emile E. Voest and Rene Bernards. DNA-guided precision medicine for cancer, a case of irrational exuberance? *Cancer Discovery*, 2016; 6:130-2.

K. Dijkstra, Paula Voabil, T. Schumacher, **E.E. Voest**. Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors: A Review. *JAMA Oncology* 2016, 2:1490-1495

van der Velden DL, Opdam FL, **Voest EE**. TAS-102 for Treatment of Advanced Colorectal Cancers that Are No Longer Responding to Other Therapies. *Clin Cancer Res.* 2016, 22(12):2835-9.

Cirkel GA, Weeber F, Bins S, Gadellaa-van Hooijdonk CG, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Ubink I, Steeghs N, de Jonge MJ, Langenberg MH, Schellens JH, Sleijfer S, Lolkema MP, **Voest EE**. The Time To Progression Ratio: a new individualized volumetric parameter for early detection of clinical benefit of targeted therapies. *Ann Oncol.* 2016; 27:1638-43.

Rhodé M. Bijlsma, Annelien L. Bredenoord, Christa G. Gadellaa-Hooijdonk, Martijn P.J. Lolkema, Stefan Sleijfer, **Emile E. Voest**, Margreet G.E.M. Ausems, Neeltje Steeghs. Unsolicited findings of Next Generation Sequencing for tumor analysis within a Dutch consortium: Clinical daily practice reconsidered. *Eur J Human Genetics* 2016, 24:1496-500.

Didier Meulendijks, Wolfgang Jacob, Maria Martinez-Garcia, Alvaro Taus, Martijn P. Lolkema, **Emile E. Voest**, Marlies H.G. Langenberg, Tania Fleitas, Andres Cervantes, Maja J. De Jonge, Stefan Sleijfer, Morten Mau Soerensen, Marlene Thomas, Maurizio Ceppi, Georgina Meneses-Lorente, Ian James, Celine Adessi, Francesca Michielin, Keelara Abiraj, Birgit Bossenmaier, Jan H.M. Schellens, Martin Weisser, Ulrik N. Lassen. First-in-human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-positive Solid Tumors. *Clin Cancer Res* 2016; 22:877-85

Wendy W. J. de Leng, Christa G. Gadellaa-van Hooijdonk, Françoise A. S. Barendregt-Smouter, Marco J. Koudijs, Ies Nijman, John W. J. Hinrichs, Edwin Cuppen, Stef van Lieshout, Robert D. Loberg, Maja de Jonge, **Emile E. Voest**, Roel A. de Weger, Neeltje Steeghs, Marlies H. G. Langenberg, Stefan Sleijfer, Stefan M. Willems, Martijn P. Lolkema. Targeted next generation sequencing as a reliable diagnostic assay for the detection of somatic mutations in tumours using minimal DNA amounts from formalin fixed paraffin embedded material. *Plos One* 2016; 1(2):e0149405

Evelyne Beerling, Daniëlle Seinstra, Elzo de Wit, Lennart Kester, Daphne van der Velden, Carrie Maynard, Ronny Schäfer, Paul van Diest, **Emile Voest**, Alexander van Oudenaarden, Nienke Vriskoop, Jacco van Rheenen. Plasticity between epithelial and mesenchymal states unlinks EMT from metastasis-enhancing stem cell capacity. *Cell reports*, 2016; 14:2281-8.

Cirkel GA, Kerklaan BM, Vanhoutte F, der Aa AV, Lorenzon G, Namour F, Pujuguet P, Darquenne S, de Vos FY, Snijders TJ, **Voest EE**, Schellens JH, Lolkema MP. A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies. *Invest New Drugs*. 2016; 34:184-92.

- **2015**

Marijn T.M. van Jaarsveld, Julia M. Houthuijzen and **Emile E. Voest**. Molecular mechanisms of target recognition by Lipid GPCRs: Relevance for cancer. *Oncogene* 2015; 35:4021-35.

Fleur Weeber, Marc van de Wetering, Marlous Hoogstraat, Krijn K. Dijkstra, Oscar Krijgsman, Thomas Kuilman, Christa G.M. Gadellaa - van Hooijdonk, Daphne L. van der Velden, Daniel S. Peeper, Edwin Cuppen, Robert G. Vries, Hans Clevers, **Emile E. Voest**. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. *Proceedings National Academy Sciences*, 2015;112(43):13308-11.

Kerklaan BM, Lolkema MP, Devriese LA, **Voest EE**, Nol-Boekel A, Mergui-Roelvink M, Langenberg M, Mykulowycz K, Stoebenau J, Lane S, Legenne P, Wissel P, Smith DA, Giantonio BJ, Schellens JH, Witteveen PO. Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours. *Br J Cancer*. 2015 Sep 1;113(5):706-15

Daenen LG, Cirkel GA, Houthuijzen JM, Gerrits J, Oosterom I, Roodhart JM, van Tinteren H, Ishihara K, Huitema AD, Verhoeven-Duif NM, **Voest EE**. Increased Plasma Levels of Chemoresistance-Inducing Fatty Acid 16:4(n-3) After Consumption of Fish and Fish Oil **JAMA Oncol**. 2015 Jun 1;1(3):350-8

Kemper K, Krijgsman O, Cornelissen-Steijger P, Shahrabi A, Weeber F, Song JY, Kuilman T, Vis DJ, Wessels LF, **Voest EE**, Schumacher TN, Blank CU, Adams DJ, Haanen JB, Peeper DS. Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. **EMBO Mol Med**. 2015;7(9):1104-18.

Weeber F, Koudijs MJ, Hoogstraat M, Besselink NJ, VAN Lieshout S, Nijman IJ, Cuppen E, Offerhaus GJ, **Voest EE**. Effective Therapeutic Intervention and Comprehensive Genetic Analysis of mTOR Signaling in PEComa: A Case Report. **Anticancer Res**. 2015; 35(6):3399-403.

Hoogstraat M, Gadellaa-van Hooijdonk CG, Ubink I, Besselink NJ, Pieterse M, Veldhuis W, van Stralen M, Meijer EF, Willems SM, Hadders MA, Kuilman T, Krijgsman O, Peeper DS, Koudijs MJ, Cuppen E, **Voest EE**, Lolkema MP. Detailed imaging and genetic analysis reveal a secondary BRAFL 505H resistance mutation and extensive intra-patient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib. **Pigment Cell Melanoma Res**. 2015; 28(3):318-23

Devriese LA, Witteveen PE, Mergui-Roelvink M, Smith DA, Lewis LD, Mendelson DS, Bang YJ, Chung HC, Dar MM, Huitema AD, Beijnen JH, **Voest EE**, Schellens JH. Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumors and impaired renal function. **Br J Clin Pharmacol**. 2015;80(2):253-66.

van der Sluis PC, Ubink I, van der Horst S, Boonstra JJ, **Voest EE**, Ruurda JP, Borel Rinkes IH, Wiezer MJ, Schipper ME, Siersema PD, Los M, Lolkema MP, van Hillegersberg R. Safety, Efficacy, and Long-Term Follow-Up Evaluation of Perioperative Epirubicin, Cisplatin, and Capecitabine Chemotherapy in Esophageal Resection for Adenocarcinoma. **Ann Surg Oncol**. 2015 May;22(5):1555-63

Ariës IM, van den Dungen RE, Koudijs MJ, Cuppen E, **Voest E**, Molenaar JJ, Caron HN, Pieters R, den Boer ML. Towards personalized therapy in pediatric acute lymphoblastic leukemia; RAS mutations and prednisolone resistance. **Haematologica**. 2015;100(4):e132-6.

Hoogstraat M, Hinrichs JW, Besselink NJ, Radersma-van Loon JH, de Voijs CM, Peeters T, Nijman IJ, de Weger RA, **Voest EE**, Willems SM, Cuppen E, Koudijs MJ. Simultaneous Detection of Clinically Relevant Mutations and Amplifications for Routine Cancer Pathology. **J Mol Diagn**. 2015;17(1):10-8

- **2014**

Houthuijzen JM, Daenen LG, Roodhart JM, Oosterom I, van Jaarsveld MT, Govaert KM, Smith ME, Sadatmand SJ, Rosing H, Kruse F, Helms BJ, van Rooijen N, Beijnen JH, Haribabu B, van de Lest CH, Voest EE. Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response. **Nat Commun**. 2014 Nov 12;5:5275

Moreno Garcia V, Olmos D, Gomez-Roca C, Cassier P, Morales-Barrera R, Del Conte G, Gallerani E, Brunetto A, Schoffski P, Marsoni S, Schellens JH, Penel N, **Voest E**, Evans TR, Plummer ER, Wilson RH, Soria JC, Tabernero J, Verweij J, Kaye SB. Dose-response relationship in phase 1 clinical trials: a European Drug Development Network (EDDN) collaboration study. **Clin Cancer Res**. 2014; 20(22):5663-71.

Ubink I, van der Sluis P, Schipper M, Reerink O, **Voest E**, Borel-Rinkes I, Wijrdeman H, Vleggaar F, Agterof M, Overkleeft E, Siersema P, van Hillegersberg R, Lolkema M. Adding Preoperative Radiotherapy Plus Cetuximab to Perioperative Chemotherapy for Resectable Esophageal Adenocarcinoma: A Single-Center Prospective Phase II Trial. **Oncologist**. 2014;19:32-3.

Hoogstraat M, de Pagter MS, Cirkel GA, van Roosmalen MJ, Harkins TT, Duran K, Kreeftmeijer J, Renkens I, Witteveen PO, Lee CC, Nijman IJ, Guy T, van 't Slot R, Jonges TN, Lolkema MP, Koudijs MJ, Zweemer RP, **Voest EE**, Cuppen E, Kloosterman WP. Genomic and transcriptomic plasticity in treatment-naive ovarian cancer. **Genome Res**. 2014; 24:200-11

Shaltiel IA, Aprelia M, Saurin AT, Chowdhury D, Kops GJ, **Voest EE**, Medema RH. Distinct phosphatases antagonize the p53 response in different phases of the cell cycle. **Proc Natl Acad Sci U S A**. 2014;111:7313-8.

Lankheet NA, Kloth JS, Gadellaa-van Hooijdonk CG, Cirkel GA, Mathijssen RH, Lolkema MP, Schellens JH, **Voest EE**, Sleijfer S, de Jonge MJ, Haanen JB, Beijnen JH, Huitema AD, Steeghs N. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. **Br J Cancer**. 2014;110:2441-9.

Ellis LM, Bernstein DS, **Voest EE**, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilienbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. **J Clin Oncol**. 2014 Apr 20;32(12):1277-80.

Cassier PA, Polivka V, Judson I, Soria JC, Penel N, Marsoni S, Verweij J, Schellens JH, Morales-Barrera R, Schöffski P, **Voest EE**, Gomez-Roca C, Evans TR, Plummer R, Gallerani E, Kaye SB, Olmos D. Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database **Ann Oncol**. 2014 Jun;25(6):1222-8.

Cirkel GA, Gadellaa-van Hooijdonk CG, Koudijs MJ, Willems SM, **Voest EE**. Tumor heterogeneity and personalized cancer medicine: are we being outnumbered? **Future Oncol**. 2014;10:417-28.

- **2013**

Lolkema MP, Gadellaa-Vanhooijdonk CG, Bredenoord AL, **Voest EE**. Reply to L. Battistuzzi et al. **J Clin Oncol**. 2013 Nov 10;31(32):4165-6

Martijn P. Lolkema, Christa G. Gadellaa - van Hooijdonk, Annelien L. Bredenoord, Peter Kapitein, Nancy Roach, Edwin Cuppen, Nine V. Knoers, **Emile E. Voest**. Ethical, legal and

counselling challenges surrounding the return of genetic results in oncology. *J Clin Oncol* 2013, 31:1842-8

Jeanine M.L. Roodhart, Huanhuan He, Laura G.M. Daenen, Arnaud Monvoisin, Chad Barber, Miranda van Amersfoort, Jennifer J. Hofmann, Freddy Radtke, Timothy F. Lane, **Emile E. Voest**[#], M. Luisa Iruela-Arispe[#]. Notch1 regulates angio-supportive bone marrow-derived cells: relevance to chemoresistance. *Blood* 2013;122:143-153

Laura G.M. Daenen, Julia M. Houthuijzen, Geert A. Cirkel, Jeanine M.L. Roodhart, Yuval Shaked, and **Emile E. Voest**. Host-mediated mechanisms reducing the efficacy of antitumor therapies. *Oncogene* 2014; 33:1341-7013

Mans DA, Vermaat JS, Weijts BG, van Rooijen E, van Reeuwijk J, Boldt K, Daenen LG, van der Groep P, Rowland BD, Jans JJ, Roepman R, **Voest EE**, van Diest PJ, Verhaar MC, de Bruin A, Giles RH. Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients. *J Pathol.* 2013;231:117-129

Stuurman FE, Lolkema MP, Huitema AD, Soetekouw PM, Rosing H, Rolfe L, Kaur P, Beijnen JH, van Tinteren H, **Voest EE**, Schellens JH. A Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO-101 in Patients With Advanced Solid Tumors. *J Clin Pharmacol.* 2013; 53:878-883

Kleiblova P, Shaltiel IA, Benada J, Evcík J, Pechácková S, Pohlreich P, **Voest EE**, Dundr P, Bartek J, Kleibl Z, Medema RH, Macurek L. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. *J Cell Biol.* 2013;201:511-21.

Sander G. Basten, Erica E. Davis , Ad J. M. Gillis, Ellen van Rooijen, Hans Stoop,,Nikolina Babala,Ive Logister, Zachary G. Heath, Trudy N. Jonges, Nicholas Katsanis, **Emile E. Voest**, Freek J. van Eeden, Rene H. Medema, Rachel Giles. Mutations in *LRRC50* Predispose Zebrafish and Humans to Seminomas. *Plos Genetics* 2013 9(4): e1003384

Kort A, Hillebrand MJ, Cirkel GA, **Voest EE**, Schinkel AH, Rosing H, Schellens JH, Beijnen JH. Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2013;925C:117-123

Stigter EC, Letsiou S, Broek NJ, Gerrits J, Ishihara K, **Voest EE**, Verhoeven-Duif NM, Brenkman AB. Development and validation of a quantitative LC-tandem MS assay for hexadeca-4,7,10,13-tetraenoic acid in human and mouse plasma. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2013;925C:16-19

Basten SG, Willekers S, Vermaat JS, Slaats GG, **Voest EE**, van Diest PJ, Giles RH. Reduced cilia frequencies in human renal cell carcinomas versus neighboring parenchymal tissue. *Cilia* 2013;2(1):2.

Stuurman FE, **Voest EE**, Awada A, Witteveen PO, Bergeland T, Hals PA, Rasch W, Schellens JH, Hendlisz A. Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors. *Invest New Drugs.* 2013 Jan 24

Devriese LA, Witteveen PO, Wanders J, Law K, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Huitema AD, **Voest EE**, Schellens JH. Pharmacokinetics of

eribulin mesylate in patients with solid tumors receiving repeated oral rifampicin. *Br J Clin Pharmacol.* 2013;75:507-515.

Tali Voloshin, **Emile E Voest**, Yuval Shaked. The host immunological response to cancer therapy: an emerging concept in tumor biology. *Exp Cell Research* 2013, Mar 19, in press

- **2012**

Snoeren N, van Hooff SR, Adam R, van Hillegersberg R, **Voest EE**, Guettier C, van Diest PJ, Nijkamp MW, Brok MO, van Leenen D, Koerkamp MJ, Holstege FC, Rinkes IH. Exploring gene expression signatures for predicting disease free survival after resection of colorectal cancer liver metastases. *PLoS One* 2012;7:e49442

Devriese LA, Witteveen PO, Marchetti S, Mergui-Roelvink M, Reyderman L, Wanders J, Jenner A, Edwards G, Beijnen JH, **Voest EE**, Schellens JH. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. *Cancer Chemother Pharmacol.* 2012;70:823-832.

Ploquin A, Olmos D, Lacombe D, A'hern R, Duhamel A, Twelves C, Marsoni S, Morales-Barrera R, Soria JC, Verweij J, **Voest EE**, Schöffski P, Schellens JH, Kramar A, Kristeleit RS, Arkenau HT, Kaye SB, Penel N. Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin. *Br J Cancer* 2012;107:1025-30.

Yost SE, Smith EN, Schwab RB, Bao L, Jung H, Wang X, **Voest E**, Pierce JP, Messer K, Parker BA, Harismendy O, Frazer KA. Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens. *Nucleic Acids Res.* 2012;40:e107.

Trajkovic-Vidakovic M, de Graeff A, **Voest EE**, Teunissen SC. Symptoms tell it all: A systematic review of the value of symptom assessment to predict survival in advanced cancer patients. *Crit Rev Oncol Hematol.* 2012; 84:130-48

Vermaat JS, Gerritse FL, van der Veldt AA, Roessingh WM, Niers TM, Oosting SF, Sleijfer S, Roodhart JM, Beijnen JH, Schellens JH, Gietema JA, Boven E, Richel DJ, Haanen JB, **Voest EE**. Validation of Serum Amyloid α as an Independent Biomarker for Progression-Free and Overall Survival in Metastatic Renal Cell Cancer Patients. *Eur Urology* 2012;62:685-695

Olmos D, A'hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, **Voest EE**, Schöffski P, Ang JE, Penel N, Schellens JH, Del Conte G, Brunetto AT, Evans TR, Wilson R, Gallerani E, Plummer R, Tabernero J, Soria JC, Kaye SB. Patient selection for oncology phase 1 trials- a multi-institutional study of prognostic factors. *J Clin Oncol* 2012; 30:996-1004.

Groenewegen G, Walraven M, Vermaat J, de Gast B, Witteveen E, Giles R, Haanen J, **Voest E**. Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma. *Br J Cancer.* 2012 106:284-9.

Vermaat JS, Nijman IJ, Koudijs MJ, Gerritse FL, Scherer S, Mokry M, Roessingh W, Lansu N, de Bruijn E, van Hillegersberg R, Van Diest PJ, Cuppen E, **Voest EE**. Primary colorectal

cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. *Clin Cancer Res.* 2012;18:688-698

- 2011

Frederik J.H. Hoogwater, Nikol Snoeren, Maarten W. Nijkamp, Amy C. Gunning, Winan J. van Houdt, Menno T. de Bruijn, **Emile E. Voest**, Richard van Hillegersberg, Onno Kranenburg, Inne H.M. Borel Rinkes. Circulating CD95-ligand as potential prognostic marker for recurrence in patients with synchronous colorectal liver metastases. *Anticancer Research*, 2011;31:4507-12

Kloosterman WP, Hoogstraat M, Paling O, Tavakoli-Yaraki M, Renkens I, Vermaat JS, van Roosmalen MJ, van Lieshout S, Nijman IJ, Roessingh W, van 't Slot R, van de Belt J, Guryev V, Koudijs M, **Voest E**, Cuppen E. Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer. *Genome Biol.* 2011;12(10):R103.

Laura G.M. Daenen, Jeanine M.L. Roodhart, Miranda van Amersfoort, Mantre Dehnad, Wijnand Roessingh, Laurien Ulfman, Patrick W.B. Derksen and **Emile E. Voest**. Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells. *Cancer Research* 2011,71:6976-85

Jeanine M.L. Roodhart, Laura G.M. Daenen, Edwin C.A. Stigter, Henk-Jan Prins, Johan Gerrits, Julia M. Houthuijzen, Marije G. Gerritsen, Henk S. Schipper, Marieke J.G. Backer, Miranda van Amersfoort, Joost S.P. Vermaat, Petra Moerer, Kenji Ishihara, Erik Kalkhoven, Jos H. Beijnen, Patrick W.B. Derksen, Rene H. Medema, Anton C. Martens, Arjan B. Brenkman, **Emile E. Voest**. Mesenchymal Stem Cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. *Cancer Cell*, 2011;20:370-383

van Rooijen E, Santhakumar K, Logister I, **Voest E**, Schulte-Merker S, Giles R, van Eeden F. A Zebrafish Model for VHL and Hypoxia Signaling. *Methods Cell Biol.* 2011;105:163-90

Devriese LA, Bosma AJ, van de Heuvel MM, Heemsbergen W, **Voest EE**, Schellens JH. Circulating tumor cell detection in advanced non-small cell lung cancer patients by multi-marker QPCR analysis. *Lung Cancer* 2011 75:242-7

Ten Berg MJ, van den Bemt PM, Shantakumar S, Bennett D, **Voest EE**, Huisman A, van Solinge WW, Egberts TC. Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital-based cohort study. *Drug Saf.* 2011,34:1151-60.

Walraven M, Witteveen PO, Lolkema MP, van Hillegersberg R, **Voest EE**, Verheul HM. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. *Angiogenesis.* 2011;14:135-41.

Koolen SL, Witteveen PO, Jansen RS, Langenberg MH, Kronemeijer RH, Nol A, Garcia-Ribas I, Callies S, Benhadji KA, Slapak CA, Beijnen JH, **Voest EE**, Schellens JH. Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. *Clin Cancer Res* 2011;17:6071-6082

Ron C.J. Schackmann, Miranda van Amersfoort, Judith H.I. Haarhuis, Eva J. Vlug, Vincent A. Halim, Jeanine M.L. Roodhart, Joost S. Vermaat, **Emile E. Voest**, Petra van der Groep, Paul J. van Diest, Jos Jonkers and Patrick W.B. Derksen. Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. *J Clin Invest* 2011;121:3176-3188

Lalisang RI, Erdkamp FL, Rodenburg CJ, Knibbeler-van Rossum CT, Nortier JW, van Bochove A, Slee PH, **Voest EE**, Wils JA, Wals J, Loosveld OJ, Smals AE, Blijham GH, Tjan-Heijnen VC, Schouten HC. Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy. *Breast Cancer Res Treat.* 2011;128:437-445

Molloy TJ, Devriese LA, Helgason HH, Bosma AJ, Hauptmann M, **Voest EE**, Schellens JH, Van't Veer LJ. A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. *Br J Cancer.* 2011;104:1913-1919

Devriese LA, **Voest EE**, Beijnen JH, Schellens JH. Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials. *Cancer Treat Rev.* 2011 37:579-89

Holleman A, Chung I, Olsen RR, Kwak B, Mizokami A, Saijo N, Parissenti A, Duan Z, **Voest EE**, Zetter BR. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. *Oncogene*, 2011 30:4386-98

Langenberg MHG, Witteveen PO, Roodhart J, Lolkema MP, Verheul HM, Mergui-Roelvink M, Brendel E, Kratzschmar J, Loembe B, Nol-Boekel A, Christensen O, Schellens JHM, Voest EE. Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. *Ann Oncol* 2011, 22:2508-15.

Boss DS, Witteveen PO, van der Sar J, Lolkema MP, **Voest EE**, Stockman PK, Ataman O, Wilson D, Das S, Schellens JH. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. *Ann Oncol.* 2011;22:431-437

- **2010**

Lens SMA, **Voest EE**, Medema RH. Shared and separate functions of Polo-like and Aurora kinases in cancer. *Nat Rev Cancer*, 2010;10:825-841

Witteveen PO, van der Mijn KJ, Los M, Kronemeijer RH, Groenewegen G, **Voest EE**. Phase 1/2 study of atrasentan combined with pegylated liposomal Doxorubicin in platinum-resistant recurrent ovarian cancer. *Neoplasia*. 2010;12:941-5.

Snoeren N, **Voest EE**, Bergman AM, Dalesio O, Verheul HM, Tollenaar RA, van der Sijp JR, Schouten SB, Rinkes IH, van Hillegersberg R. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. *BMC Cancer.* 2010 Oct 11;10:545.

Wessels H, de Graeff A, Wynia K, de Heus M, Kruitwagen CL, Teunissen SC, **Voest EE**. Are health care professionals able to judge cancer patients' health care preferences correctly? A cross-sectional study. *BMC Health Serv Res*. 2010 Jul 8;10:198

Wessels H, de Graeff A, Wynia K, de Heus M, Kruitwagen CL, Woltjer GT, Teunissen SC, **Voest EE**. Gender-related needs and preferences in cancer care indicate the need for an individualized approach to cancer patients. *Oncologist*. 2010;15:648-55.

Wessels H, de Graeff A, Groenewegen G, Wynia K, de Heus M, Vos JB, Tjia P, Kruitwagen CL, Teunissen SC, **Voest EE**. Impact of integration of clinical and outpatient units on cancer patient satisfaction. *Int J Qual Health Care*. 2010;22:358-364.

Kroeze SG, Vermaat JS, van Brussel A, van Melick HH, **Voest EE**, Jonges TG, van Diest PJ, Hinrichs J, Bosch JL, Jans JJ. Expression of nuclear FIH independently predicts overall survival of clear cell renal cell carcinoma patients. *Eur J Cancer*, 2010; 46:3375-3381

Daenen LG, Roodhart J, Shaked Y, **Voest EE**. Vascular Disrupting Agents (VDAs) in Anticancer Therapy. *Curr Clin Pharmacol* 2010;5:178-185

Ellen van Rooijen, **Emile E. Voest**, Ive Logister, Jeroen Bussmann, Jeroen Korving, Fredericus J. van Eeden, Rachel H. Giles and Stefan Schulte-Merker. von Hippel-Lindau tumor suppressor mutants faithfully model pathological hypoxia-driven angiogenesis and vascular retinopathies in zebrafish. *Dis Model Mech* 2010; 3:343-353

Langenberg MH, Witteveen PO, Roodhart JM, Verheul HM, Mergui-Roelvink M, van der Sar J, Brendel E, Laferriere N, Schellens JH, **Voest EE**. Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors. *Clin Cancer Res*, 2010; 16:2187-2197

Langenberg MH, Nijkamp MW, Roodhart JM, Snoeren N, Tang T, Shaked Y, van Hillegersberg R, Witteveen PO, Vermaat JS, Kranenburg O, Kerbel RS, Medema RH, Borel Rinkes IH, **Voest EE**. Liver surgery induces an immediate mobilization of progenitor cells in liver cancer patients: A potential role for G-CSF. *Cancer Biol Ther* 2010;9:743-748

Morgan Nordstrom-O'Brien, Robert B. van der Luijt, Ans M. van den Ouweland, Martijn P. Lolkema, **Emile E. Voest**, and Rachel H. Giles. Genetic Analysis of von Hippel-Lindau Disease. *Human Mutations*, 2010, 31:521-537

Langenberg MH, Witteveen PO, Lankheet NA, Roodhart JM, Rosing H, van den Heuvel IJ, Beijnen J, **Voest EE**. Phase 1 Study of Combination Treatment with PTK 787/ZK 222584 and Cetuximab for Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics Analysis. *Neoplasia* 2010; 12: 206-213

Roodhart JM, Langenberg MH, Vermaat JS, Lolkema MP, Baars A, Giles RH, Witteveen EO, **Voest EE**. Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients. *Neoplasia* 2010; 12:87-94

B. Kuenen, P.O. Witteveen, R.Ruijter, G. Giaccone, A.Dontabhaktuni, F.Fox, T.Katz, H.Youssoufian, J. Zhu, E.K. Rowinsky, **E.E. Voest**. A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies. *Clin Cancer Res* 2010;16:1915-1923

van Cruijssen H, **Voest EE**, Punt CJ, Hoekman K, Witteveen PO, Meijerink MR, Puchalski TA, Robertson J, Saunders O, Jurgensmeier JM, van Herpen CM, Giaccone G. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. *Eur J Cancer*, 2010;46:901-911

Overkleeft EN, Goldschmeding R, van Reekum F, **Voest EE**, Verheul HM. Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. *Ann Oncol* 2010; 21:184-5

J. S. Vermaat, I. van der Tweel, N. Mehra, S. Sleijfer, J. B. Haanen, J. M. Roodhart, J. Y. Engwegen, C. M. Korse, M. H. Langenberg, W. Kruit, G. Groenewegen, R. H. Giles, J. H. Schellens, J. H. Beijnen and **E. E. Voest**. Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. *Ann Oncol* 2010, 21:1472-1481

Oostendorp RL, Witteveen PO, Schwartz B, Vainchtein LD, SchotM, Nol A, Rosing H, Beijnen JH, **Voest EE**, Schellens JH. Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors. *Invest New Drugs* 2010; 28:163-170

- **2009**

Laura G. Daenen, Yuval Shaked, Shan Man, Ping Xu, **Emile E. Voest**, Robert M. Hoffman, David Chaplin, and Robert S. Kerbel. Low-Dose Metronomic Cyclophosphamide Combined with Vascular Disrupting Therapy Induces Potent Anti-Tumor Activity in Preclinical Human Tumor Xenograft Models. *Mol Cancer Ther* 2009;8:2872-2881

Lankheet AG, Hillebrand MJ, Langenberg MH, Rosing H, Huitema AD, Voest EE, Schellens J, Beijnen JH. A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2009; 877:3625-3630

Yuval Shaked, Terence Tang, Jill Woloszynek, Laura G. Daenen, Shan Man, Ping Xu, Shi-Rong Cai, Jeffrey M. Arbeit, **Emile E Voest**, David Chaplin, Jon Smythe, Adrian Harris, Paul Nathan, Ian Judson, Gordon Rustin, Francesco Bertolini, Daniel C Link, Robert S. Kerbel. Contribution of G-CSF to the acute mobilization of endothelial precursor cells by vascular disrupting agents. *Cancer Research* 2009;69: 7524-7528

Shaked Y and **Voest EE**. Bone marrow derived cells in angiogenesis and growth: are they the good, the bad or the evil ? *BBA Reviews on Cancer* 2009; 1796: 1-4

Engwegen JY, Mehra N, Haanen JB, Schellens JH, **Voest EE**, Beijnen JH. Identification of two new serum profiles for renal carcinoma. *Oncol Reports*. 2009; 22: 401-408

Marlies H.G. Langenberg, Carla M.L. van Herpen, Johann De Bono, Jan H.M. Schellens, Clemens Unger, Klaas Hoekman, Hubert E. Blum, Walter Fiedler, Joachim Dreves, Florence Le Maulf, Anitra Fielding, Jane Robertson, and **Emile E. Voest**. Effective strategies for management of hypertension following VEGF signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors. *J Clin Oncol* 2009; 27:6152-9

Linsen SE, de Wit E, Janssens G, Heater S, Chapman L, Parkin RK, Fritz B, Wyman SK, de Bruijn E, **Voest EE**, Kuersten S, Tewari M, Cuppen E. Limitations and possibilities of small RNA digital gene expression profiling. *Nature Methods* 2009; 6:474-476

Homs MY, **Voest EE**, Siersema PD. Emerging drugs for esophageal cancer *Expert Opin Emerg Drugs*. 2009; 14:329-339

H. Wessels, A. de Graeff, K. Wynia, HJ Sixma, M. de Heus, M, Schipper, GT Woltjer, Teunissen SC, **EE Voest** Medical oncology patients' preferences with regard to health care: development of a patient-driven questionnaire. *Ann Oncol* 2009; 20:1708-1713

Jeanine M Roodhart, Marlies Langenberg, Laura G Daenen, **Emile Voest**. Translating preclinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back. *BBA - Reviews on Cancer*, 2009; 1796 (1): 41-49

Nijkamp MW, van der Bilt JD, de Bruijn MT, Molenaar IQ, **Voest EE**, van Diest PJ, Kranenburg O, Borel Rinkes IH. Accelerated Perinecrotic Outgrowth of Colorectal Liver Metastases Following Radiofrequency Ablation is a Hypoxia-Driven Phenomenon. *Ann Surg* 2009; 249: 814-823

Ellen van Rooijen¹⁻², **Emile E. Voest**¹, Ive Logister¹⁻², Jeroen Korving², Thorsten Schwerte³, Stefan Schulte-Merker², Rachel H. Giles^{1*} and Freek J. van Eeden² Zebrafish mutants in the von Hippel-Lindau (VHL) tumor suppressor display a hypoxic response and recapitulate key aspects of Chuvash polycythemia, *Blood* 2009; 113: 6449-6460

Oostendorp RL, Loftiss J, Goel S, Smith DA, Dar MM, Witteveen PO, Cohen RB, Lewis LD, Kurian S, Patnaik A, Rosing H, Beijnen JH, **Voest EE**, Burris H, J. Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors. *Int J Clin Pharmacol Ther*. 2009; 47:195-206.

Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, **Voest EE**, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. *N Engl J Med* 2009; 360:563-572

- **2008**

Yuval Shaked, Erik Henke, Jeanine Roodhart, Patrizia Mancuso, Marlies Langenberg, Marco Colleoni, Laura G. Daenen, Shan Man, Ping Xu, Urban Emmenegger, Terence Tang, Zhenping Zhu, Larry Witte, Robert M. Strieter, Francesco Bertolini, **Emile Voest**, Robert Benezra and Robert S. Kerbel. Rapid chemotherapy-induced acute endothelial progenitor cell

mobilization: implications for antiangiogenic drugs as chemosensitizing agents. *Cancer Cell* 2008; 14: 263-73

Roodhart JM, Langenberg MH, Witteveen E, **Voest EE**. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. *Curr Clin Pharmacol* 2008; 3:132-143

Nieboer P, de Vries EG, Mulder NH, Rodenhuis S, Bontenbal M, van der Wall E, van Hoesel QG, Smit WM, Hupperets P, **Voest EE**, Nooij MA, Boezen HM, van der Graaf WT. Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients. *Bone Marrow Transplant*. 2008; 42: 475-481

SA Veltkamp, P.O Witteveen, A Capriati, S Bini, M Voogel-Fuchs, R Kronemeyer, JH Beijnen, **EE Voest**, JHM Schellens. Clinical and pharmacological study of the novel prodrug MEN 4901/T-0128 in patients with solid tumors. *Clin Cancer Res* 2008, 14: 7535-7544

N. Snoeren, **E.E.Voest**, R. van Hillegersberg. Surgery vs surgery and chemotherapy for colorectal liver metastases. *Lancet* 2008; 372: 202-3

Greijer AE, Delis-van Diemen PM, Fijneman RJ, Giles RH, **Voest EE**, van Hinsberg VW, Meijer GA. Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum. *Virchows Arch*. 2008; 452:535-544

D.A. Mans, **E.E. Voest**, R.H. Giles. All along the watchtower: Is the cilium a tumor suppressor organelle? *Biochim Biophys Acta*. 2008; 1786:114-125

Mans DA, Lolkema MP, van Beest M, Daenen LG, **Voest EE**, Giles R. Mobility of the von Hippel-Lindau tumour suppressor protein is regulated by kinesin-2. *Exp Cell Res* 2008, 314:1229-1236

Ellen van Rooijen, Rachel H. Giles, **Emile E. Voest**, Carina van Rooijen, Stefan Schulte-Merker and Freek J. van Eeden. LRRC50, a conserved ciliary protein implicated in polycystic kidney disease. *J Am Soc Nephrol* 2008, 19:1128-1138

Lolkema MP, Mans DA, Ulfman LH, Volpi S, **Voest EE**, Giles RH. Allele-specific regulation of primary cilia function by the von Hippel-Lindau tumor suppressor. *Eur J Hum Genet*. 2008;16:73-78

- **2007**

Buijs C, Rodenhuis S, Seynaeve CM, van Hoesel QG, van der Wall E, Smit WJ, Nooij MA, **Voest E**, Hupperets P, Ten Vergert EM, van Tinteren H, Willemsse PH, Mourits MJ, Aaronson NK, Post WJ, de Vries EG. Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life. *J Clin Oncol* 2007;24:5403-5439

- Henk M.W. Verheul, Martijn P.J. Lolkema, David Z. Qian, Yvonne H.A. Hilkes, Eleni Liapi, Jan-Willem N. Akkerman, Roberto Pili and **Emile E. Voest**. Platelets take up the monoclonal antibody bevacizumab. *Clin Cancer Res*, 2007;13:5341-5347
- Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, van Maanen R, Vermaat JS, Witteveen PO, Visseren-Grul CM, Musib L, Enas N, van Hal G, Beijen JH, Schellens JH, **Voest EE**. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. *Clin Cancer Res* 2007;13:4474-4481
- Martijn P Lolkema, , Dorus A Mans, Cristel M Snijckers, Mascha van Noort, Moniek van Beest, Emile E Voest, Rachel Giles,. The von Hippel-Lindau tumor suppressor interacts with kinesin-2 family member KIF3A to regulate primary cilia. *FEBS Lett* 2007;581:4571-4576
- S. Teunissen, A. de Graeff, **E.E. Voest**, J.C. de Haes. Are anxiety and depressed mood related to physical symptom burden? A study in hospitalized advanced cancer patients. *Palliat Med*. 2007;21:341-6.
- de Groot JWB, Zonnenberg BA, Quarles –van Ufford P, de Vries MM, Links TP, Lips CJM, Voest EE. A Phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. *J Clin Endocrin Metab*, 2007;92:3466-3469
- Tjin a Ton M, Montfrans C, Koldenhof J, Sigurdsson V, **Voest EE**, Witteveen PO. Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors. *Ned Tijdschr Geneesk*. 2007;151:945-52.
- Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, **Voest EE**, de Graeff A. Symptom Prevalence in Patients with Incurable Cancer: A Systematic Review. *J Pain Symptom Manage*. 2007;34:94-104
- Engwegen JY, Mehra N, Haanen JB, Bonfrer JM, Schellens J, **Voest EE**, Beijnen JH. Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. *Lab Invest*. 2007;87:161-72.
- I.E.L.M. Kuppens, P.O. Witteveen, R.C. Jewell, S.A. Radema, E.M. Paul, S.G. Mangum, J.H. Beijnen, **E.E. Voest**, J. Schellens. A phase I, randomized, open-label, parallel-cohort, dose-finding study of eacridar (GF120918) and oral topotecan in cancer patients. *Clin Cancer Res*, 2007;13:3276-85
- Niven Mehra, Maarten Penning, Jolanda Maas, Nancy van Daal, Rachel H Giles and **Emile E Voest**. Circulating mitochondrial nucleic acids have prognostic value for survival in advanced prostate cancer patients. *Clin Cancer Res* 2007;13:421-426
- P. van Diest, A. Kummer, **E.E. Voest**. Re: Tissue Banks Trigger Worry About Ownership Issues. *J Natl Cancer Inst*, 2007; 99:253
- M.Los, J. Roodhart, P.O. Witteveen, **E.E. Voest**. Target Practice: Lessons from Phase III Trials with Bevacizumab and Vatalanib in the Treatment of Advanced Colorectal Cancer. *The Oncologist* 2007,12:443-450

I.E.L.M. Kuppens, P.O. Witteveen, M. Schot, V. M. Schuessler, A. Daehling, J.H. Beijnen, **E.E. Voest**, J.H.M. Schellens. Phase I Dose-finding and Pharmacokinetic Trial of Orally Administered Indibulin (D-24851) to Patients with Solid Tumors. *Invest New Drugs*, 2007;25:227-235

Teunissen SC, Verhagen EH, Brink M, van der Linden BA, **Voest EE**, de Graeff A. Telephone consultation in palliative care for cancer patients: 5 years of experience in the Netherlands. *Support Care Cancer* 2007;15:577-582.

- **2006**

Hannemann J, Kristel P, van Tinteren H, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, **Voest EE**, van der Wall E, Hupperets P, de Vries EG, Rodenhuis S, van de Vijver MJ. Molecular subtypes of breast cancer and amplification of topoisomerase IIalpha: predictive role in dose intensive adjuvant chemotherapy. *Br J Cancer* 2006;95:1334-41

Does age matter in palliative care ? S. Teunissen, HC de Haes, **EE Voest**, A de Graeff. *Crit Rev Oncol Hematol* 2006;60:152-158.

Dieta Brandsma, **Emile E Voest**, Wilco de Jager, Hans Bonfrer, Ale Algra, Willem Boogerd, Tiny Korse, Jaap C Reijneveld, Marcel M Verbeek, Ger Rijkers, Martin JB Taphoorn. CSF protein profiling using Multiplex Immuno-assay – a potential new diagnostic tool for leptomeningeal metastases. *J Neurology* 2006;253:1177-84

SCCM Teunissen, A de Graeff, EJM de Nijs, JCJM de Haes, **EE Voest**. Prognostic significance of symptoms of hospitalized advanced cancer patients. *Eur J Cancer* 2006, 42:2510-2516

Niven Mehra, Maarten Penning, Jolanda Maas, Laurens V Beerepoot, Nancy van Daal, Carla H van Gils, Rachel H Giles, and **Emile E Voest**. Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. *Clin Cancer Res* 2006;12:4859-4866.

Laurens V. Beerepoot, Sandra A. Radema, Els O. Witteveen, Tawnie Thomas, Catherine Wheeler, Sanford Kempin, and **Emile E. Voest**. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. *J Clin Oncol* 2006;24:1491–1498

Dieta Brandsma^{1,2} Jaap C Reijneveld¹, Laurien Ulfman, ³ Madelon Bracke³, Martin JB Taphoorn^{1,2} Jaap Jan Zwaginga⁴, Leo Koenderman³, **Emile E Voest**² Constitutive activated integrins on leukemic cells promote leptomeningeal leukemia. *Neuro-oncology*, 2006;8:127-136

Verhaar-Langereis M., Karakus A., van Eikeren M., **Voest E.E.**, Witteveen P.O. Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer. *Int J Gynecol Cancer*. 2006;16:65-70.

Sjoerd Rodenhuis, M.D., Marijke Bontenbal, M.D., Louk V.A.M. Beex, M.D., Willem M. Smit, M.D., Marianne A. Nooij, M.D., **Emile E. Voest**, M.D., Elsken van der Wall, M.D., Pierre Hupperets, M.D., Harm van Tinteren, M.Sc., Johannes L. Peterse, M.D., Mark J. van de Vijver, M.D. and Elisabeth G.E. de Vries, M.D., for the Netherlands Working Party on Autologous Transplantation in Solid Tumors. Efficacy of High-Dose Alkylating Chemotherapy in HER2/neu-negative Breast Cancer. *Annals Oncol* 2006;17:588-596

Rachel H. Giles 1, Martijn P. Lolkema 1, Cristel M. Snijckers 1, Anita S. Jorna 1, Petra van der Groep 2, Moniek van Beest 1, Mascha van Noort 3, Roel Goldschmeding 2, Paul J. van Diest 2, Hans Clevers 4, **Emile E. Voest** 1. Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis. *Oncogene*, 2006;25:3065-70

D. Brandsma, M.J.B. Taphoorn, W. de Jager, H. Bonfrer, A.Algra, J. Reijneveld, W. Boogerd, Korse T, M.M. Verbeek, G.T. Rijkers, **E.E. Voest**. Interleukin-8 CSF levels predict survival in patients with leptomeningeal metastases. *Neurology*. 2006;66:243-6.

- **2005**

Giles RH, **Voest EE**. Tumor suppressor APC and VHL: gatekeepers of the intestine and kidney. *Prog Mol Subcell Biol*, 2005;40:151-181

P.Nieboer, C. Buijs, S. Rodenhuis, C. Seynaeve, L.V.A.M. Beex, E. van der Wall, D.J. Richel, M.A. Nooij, **E.E.Voest**, P. Hupperets, N.H. Mulder, W.T.A. van der Graaf, E.M. TenVergert, H. van Tinteren, E.G.E. de Vries. Fatigue and Relating Factors in High-Risk Breast Cancer Patients Treated With Adjuvant Standard or High-Dose Chemotherapy: A Longitudinal Study. *J Clin Oncol* 2005, 23:8296-8304

J.C. Reijneveld, MD, PhD, D. Brandsma, MD, W. Boogerd, MD, PhD, J.G.M. Bonfrère, MD, PhD, S. Kalmijn, MD, PhD, **E.E. Voest**, MD, PhD, A. Geurts-Moespot, M.C. Visser, MD, PhD, and M.J.B. Taphoorn. CSF levels of angiogenesis related proteins in patients with leptomeningeal metastases. *Neurology*, 2005;65:1120-2

M. Los, **E.E. Voest**, I.H.M. Borel Rinkes. VEGF as a Target of Therapy in Gastrointestinal Oncology. *Dig Surg*. 2005;22:282-293

N. Smakman, I.H.M. Borel Rinkes, **E.E. Voest**, O.Kranenburg. Control of colorectal metastasis formation by K-Ras. *Biochim Biophys Acta*. 2005;1756:103-114

Jarmila D.W. van der Bilt, Onno Kranenburg, Elisabeth A. te Velde, Maarten W. Nijkamp, Niels Smakman, Liesbeth M. Veenendaal, E. te Velde, **Emile E. Voest**, Paul J. van Diest, Inne H.M. Borel Rinkes. Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. *Hepatology* 2005, 42:165-175

Lolkema MP, Gervais ML, Snijckers CM, Hill RP, Giles RH, **Voest EE***, Ohh M*. Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain. *J Biol Chem*. 2005, 280:22205-22211 (* contributed equally)

O. Kranenburg, Y.J. Gent, E.P. Romijn, **E. E. Voest**, A. Heck and M. F.B.G. Gebbink. Beta-Amyloid (A β) causes neuronal cell detachment by acting as a scaffold for cell-associated plasminogen activation. *Neuroscience* 2005;131(4):877-86

Kranenburg O, Bouma B, Gent YY, Aarsman CJ, Kaye R, Posthuma G, Schiks B, **Voest EE**, Gebbink MF. beta-Amyloid (Abeta) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation. *Mol Cell Neurosci*. 2005;28:496-508

EA Koop, MFBG Gebbink, TE Sweeney, MJ Mathy, HGF Heijnen, JAE Spaan, **EE Voest**, E van Bavel, SL Peters. Impaired flow-induced dilation in mesenteric arteries from receptor protein tyrosine phosphatase μ -/- mice. *Am J Physiol Heart Circ Physiol* 2005; 288: H1218-1223

Elisabeth A. te Velde ^{1,2}, Arie Reijerkerk ², Dieta Brandsma ^{2,3}, J. Mathijs Vogten ^{1,2}, Yaping Wu ⁴, Onno Kranenburg ², **Emile E. Voest** ², Martijn Gebbink ², and Inne H.M. Borel Rinkes ¹ Early Endostatin Treatment Inhibits Metastatic Seeding of Murine Colorectal Cancer cells in the liver and their Adhesion to Endothelial cells. *Br J Cancer* 2005; 92:729-35

- **2004**

Faneyte IF, Peterse JL, Van Tinteren H, Pronk C, Bontenbal M, Beex LV, van der Wall E, Richel DJ, Nooij MA, **Voest EE**, Hupperets P, Ten Vergert EM, de Vries EG, Rodenhuis S, van de Vijver MJ. Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. *Clin Cancer Res*. 2004;10:4457-63

H.B. Kal, H. Struikmans, M.F.B.G. Gebbink and **E.E. Voest**. Response of Rat Prostate and Lung Tumors to Ionizing Radiation Combined with the Angiogenesis Inhibitor AMCA. *Strahlenther Onkol*. 2004;180:798-804

HJ Bloemendal¹, HC de Boer¹, EA Koop¹, A van Dongen², R Goldschmeding³, WJM Landman⁴, T Logtenberg¹, MFBG Gebbink¹ and **EE Voest**¹ Activated vitronectin as a target for anticancer therapy with human antibodies. *Cancer Immunol Immunother* 2004;53:799-808

M. Langenberg¹, C.H.J. Terhaard², G.J. Hordijk³, R.J.J. van Es⁴, **E.E. Voest**¹, A. de Graeff¹ Simultaneous radio-and chemotherapy for squamous cell carcinoma of the head and neck in daily clinical practice: 5 years experience in a university hospital. *Clin Otolaryngol* 2004;29:729-734

L.V. Beerepoot, N. Mehra, A. Jorna, **E.E. Voest**. Circulating endothelial cells in cancer patients do not express tissue factor. *Cancer Lett* 2004;213: 241-248

Dieta Brandsma M.D.^{1,2}, Martin J.B. Taphoorn M.D.¹, Jaap C. Reijneveld M.D.^{1,2}, Thomas M. Nas, Ing. ³, **Emile E. Voest** M.D. ², Klaas Nicolay PhD.⁴ and Erwin Blezer PhD³. MR imaging of mouse leptomeningeal metastases. *J Neurooncol*, 2004, 68:123-130

Martijn P Lolkema, Niven Mehra, Anita S Jorna, Moniek van Beest, Rachel H Giles, **Emile E Voest**. The von Hippel-Lindau tumor suppressor protein influences microtubule dynamics at the cell periphery. *Exp Cell Res* 2004; 301:139-146

MF Gebbink, **EE Voest**, A Reijerkerk. Do anti-angiogenic protein fragments have amyloid properties ? Blood 2004;104:1601-1605

T. Kerbusch^{1,2*}, G. Groenewegen³, R.A.A. Mathôt¹, V.M.M. Herben¹, W.W. ten Bokkel Huinink², M. Swart², B. Ambaum³, H. Rosing¹, S. Jansen¹, E.E. Voest³, J.H. Beijnen^{1,4}, J.H.M. Schellens^{2,4}. Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. Br J Cancer 2004, 90, 2268 - 2277

Reijerkerk A, Meijers JC, Havik SR, Bouma BN, **Voest EE**, Gebbink MFBG
Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice. J Thromb Haemost. 2004;2:769-79.

Wu YP, Bloemendal H, **Voest EE**, Logtenberg T, de Groot PhG, Gebbink MFBG, de Boer H. Fibrin-Associated Vitronectin is Involved in Platelet Adhesion and Thrombus Formation Through Homotypic Interactions with Platelet-Associated Vitronectin. Blood 2004; 104:1034-1041

Sjoerd Rodenhuis*, M.D., Marijke Bontenbal, M.D., Louk V.A.M. Beex, M.D., Elsken van der Wall, Dick J. Richel, M.D., Marianne A. Nooij, M.D., **Emile E. Voest**, M.D., Pierre Hupperets, M.D., Harm van Tinteren, M.Sc., Hans L. Peterse, M.D., Elisabeth M. TenVergert, Ph.D., and Elisabeth G.E. de Vries, M.D., for the Netherlands Working Party on Autologous Transplantation in Solid Tumors. High-dose Chemotherapy with Hematopoietic Stem-Cell Rescue in High-Risk Breast Cancer. American Journal of Oncology Review 2004;3:29-35

E.E. Voest. Angiogenesis: from understanding to targeting. Editorial. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2004;1654:1

O. Kranenburg, M.F.Gebbink, **E.E. Voest**. Stimulation of angiogenesis by Ras proteins. Biochimica et Biophysica Acta (BBA), Reviews on Cancer, 2004;1654:23-37

J. Mathys Vogten, Tamas A. Drixler, Elizabeth A. te Velde, Marguerite E. Schipper, Theo J.M.V. van Vroonhoven, **Emile E. Voest**, and Inne H.M. Borel Rinkes. Angiostatin inhibits experimental liver fibrosis in mice. Int J Colorectal Dis 2004, jan 10

Hans A.R. Bluysen^{1,4}, Martijn PJK Lolkema¹, Moniek van Beest¹, Michelle Boone¹, Cristel Snijckers¹, Maartje Los¹, Martijn FGB Gebbink¹, Branko Braam², Frank CP Holstege³, Rachel Giles and **Emile E. Voest**¹. Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. FEBS Lett 2004, 556, 137-142.

H. Verheul, **EE.Voest**, R. Schlingemann. Are tumors angiogenesis dependent? Cancer treatment by attacking it's hallmarks. J Pathol. 2004;202:5-13.

LV Beerepoot, N Mehra, JSP Vermaat, BA Zonnenberg, MF Gebbink and **EE Voest***. Increased levels of viable circulating endothelial cells are an indicator for progressive disease in cancer patients. Ann Oncol. 2004;15:139-45.

- **2003**

Tamas A. Drixler, J. Mathys Vogten, Martijn F.B.G. Gebbink, Theo J.M.V. van Vroonhoven, Peter Carmeliet, **Emile E. Voest** and Inne H.M. Borel Rinkes. Plasminogen mediates liver

regeneration and angiogenesis after partial hepatectomy in mice. *Br J Surgery* 2003, 90:1384-90.

J. Mathijs Vogten, Arie Reijerkerk, Joost C.M. Meijers, Emile E. Voest, Inne H.M. Borel Rinkes, Martijn F. B.G. Gebbink. The role of the fibrinolytic system in corneal angiogenesis. *Angiogenesis* 2003; 6: 311-316

ten Bokkel Huinink WW, van Groeningen CJ, Voest EE, Peters WG, Keizer HJ, de Witte JH. Compassionate use programme of irinotecan in colorectal cancer patients in The Netherlands. *Neth J Med.* 2003 Jul;61(7):249-56.

Te Velde EA, Wagenaar GT, Reijerkerk A, Roose-Girma M, Borel Rinkes IH, **Voest EE**, Bouma BN, Gebbink MF, Meijers JC. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. *J Thromb Haemost.* 2003,1:2087-96

L.V.Beerepoot, P.O. Witteveen, G.Groenewegen, W.E.Fogler, B.K.L.Sim, C.Sidor, E.Phillips, B.A.Zonnenberg, F.Schramel, M.F.B.G.Gebbink, **E.E.Voest** Pharmacologic and Long-term safety report of a phase I trial applying an antiangiogenic schedule of recombinant human Angiostatin in patients with advanced cancer by twice-daily subcutaneous injection *Clin Cancer Res* 2003, 9:4025-4033

Bernard A. Zonnenberg, Gerard Groenewegen, Todd J. Janus, Rod A. Humerickhouse, Jeffrey D. Isaacson, Robert A. Carr, Terri W. Leahy, **Emile Voest** Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Atrasentan (ABT-627): A Receptor Antagonist for Refractory Prostate Cancer. *Clin Cancer Res* 2003, 9:2965-72

S.A. Radema, P.O. Witteveen, M.B.F.G. Gebbink en **E.E. Voest**. Het klinisch perspectief van angiogenese remmers. *Ned Tijdschr Geneeskd* 2003, 147:1675-1680

Barend Bouma¹, Loes M.J. Kroon-Batenburg², Ya-Ping Wu³, Onno Kranenburg¹, Philip G. de Groot³, **Emile E. Voest**¹, Martijn F.B.G. Gebbink^{1,‡} Glycation induces formation of cross-β structure in albumin. *J Biol Chem*, 2003, 278:41810-9

J. Mathys Vogten, Niels Smakman, **Emile E. Voest** and Inne H.M. Borel Rinkes. Intravital analysis of microcirculation in the regenerating mouse liver. *J Surg Res.* 2003,113:264-9

EA Koop, SM Chuva de Sousa, E Feiken, HAR Bluysen, **EE Voest**, CL Mummery, WH Moolenaar, MFBG Gebbink. Receptor protein tyrosine phosphatase expression as a marker for endothelial cell heterogeneity; analysis of RPTPμ gene expression using LacZ knock-in mice. *Int J Dev Biol*, 2003;47:345-354

S Rodenhuis, M Bontenbal, LVAM van Beex, J Wagstaff, D Richel, MA Nooij, **EE Voest**, P Hupperets, H van Tinteren, HL Peterse, EM ten Vergert, EGE de Vries. High-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin in high risk breast cancer: a study of the Netherlands Working Party for Autotransplantation in solid tumors. *N Engl J Med* 2003; 349: 7-16

Onno Kranenburg, Loes M.J. Kroon-Batenburg, Arie Reijerkerk, Ya Ping Wu, **Emile E. Voest** and Martijn F.B.G. Gebbink. Recombinant endostatin forms amyloid fibrils that are cytotoxic to murine neuroblastoma cells *in vitro*. FEBS Lett 2003;539:149-55

Bernard A Zonnenberg MD, **Emile E Voest**, MD, PhD. The role of endothelin in hormone-refractory prostate cancer. European Urology Supplements 2003, 2; 9 – 14.

Arie Reijerkerk^{1*}, Laurent O. Mosnier^{2*}, Onno Kranenburg¹, Bonno N. Bouma², Peter Carmeliet³, Tom Drixler^{1,4}, Joost C.M. Meijers^{2,5}, **Emile E. Voest**¹ & Martijn F.B.G. Gebbink¹ Amyloid endostatin induces endothelial cell detachment by stimulation of the plasminogen activation system. Mol Cancer Res. 2003 ,1:561-568

Reijneveld J, Taphoorn M, Boogerd W, **Voest EE**. Angiostatin prolongs survival of mice with leptomenigeal metastases. Eur J Clin Invest 2003, 33:76-81

- **2002**

Mirjam Crul, Laurens V Beerepoot, Ellen Stokvis, Johannes SP Vermaat, Hilde Rosing, Jos H Beijnen, **Emile E Voest**, Jan HM Schellens
Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518. Cancer Chemother Pharmacol. 2002;50:473-8.

Brandsma D, Reijneveld J, Taphoorn M, Gebbink MFBG, **Voest EE**. Vascular cell adhesion molecule-1 is a key adhesion molecule in melanoma cell adhesion to the leptomeninges. Lab Invest. 2002;82:1493-502.

Van Moorselaar J and **Voest EE**. Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches. Mol Cell Endocrinol. 2002;197:239-50.

Onno Kranenburg, Barend Bouma, Loes M.J. Kroon-Batenburg, Arie Reijerkerk, Ya Ping Wu, **Emile E. Voest** and Martijn F.B.G. Gebbink.
Tissue-type plasminogen activator (tPA) is a multiligand cross- β sheet receptor. Curr Biol. 2002; 12:1833-9.

Drixler TA, Vogten MJ, Ritchie ED, Gebbink MF, van Vroonhoven TJ, **Voest EE**, Borel Rinkes IHM. Liver regeneration is an angiogenesis- associated phenomenon. Ann Surg. 2002 ;236:703-12.

Meerum Terwogt JM, Groenewegen G, Pluim D, Maliepaard M, Tibben MM, Huisman A, ten Bokkel Huinink WW, Schot M, Welbank H, **Voest EE**, Beijnen JH, Schellens JHM. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol 2002; 49: 201-210

Teunis M, Kavelaars A, **Voest EE**, Bakker JM, Ellenbroek BA, Cools AR, Heijen CJ. Reduced tumor growth, experimental metastasis formation, and angiogenesis, in rats with a hyperreactive dopaminergic system. FASEB J, 2002;16:1465-1467

de Beer EL, Bottone AE, van Rijk MC, van der Velden J, **Voest EE**. Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics. Br J Pharmacol 2002;135:1707-14

te Velde EA, **Voest EE**, van Gorp JM, Verheem A, Hagendoorn J, Gebbink MF, Borel Rinkes IH Adverse effects of the antiangiogenic agent angiostatin on the healing of experimental colonic anastomoses. *Ann Surg Oncol* 2002;9:303-9.

Te Velde EA, Vogten JM, Gebbink MFBG, Verheem A, van Gorp JM, **Voest EE** and Borel Rinkes IHM. Enhanced anti-tumour efficacy by combining conventional chemotherapy with angiostatin and endostatin in a murine liver metastasis model. *Br J Surgery*, 2002; 89:1302-1309

- **2001**

Los M, **Voest EE**. The potential role of vascular therapy in the adjuvant and neoadjuvant treatment of cancer. *Semin. Oncol* 2001; 28:93-105

Drixler TD, Borel Rinkes IHM, Ritchie ED, Treffers FW, van Vroonhoven TJ, Gebbink MFBG, Voest EE. *Invest Ophthalmol Vis Sci* 2001, 42:3325-3330

- **2000**

Drixler TA, **Voest EE**, van Vroonhoven TJMV, Borel Rinkes IHM. Angiogenesis & Surgery:from mice to man. *Eur J Surgery* 2000, 166:435-446

Reijneveld JC, **Voest EE**, Taphoorn MJB. Angiogenesis in malignant primary and metastatic brain tumors. *J. Neurol* 2000, 247:597-608

Bottone AE, van der Velden J, **Voest EE**, de Beer EL. Doxorubicine impairs crossbridge turnover kinetics in skinned cardiac trabeculae after acute and chronic treatment. *Mol Pharmacol* 2000;57:1152-1157

Los M, Kerckhaert OAJ, Zewald R, Ploos van Amstel HK, **Voest EE**. Somatic mutations of the VHL tumor suppressor gene are absent in tumor-derived endothelial cells of von Hippel-Lindau patients. *J Natl Cancer Inst* 2000; 92: 1688-1689

Drixler T, Borel Rinkes IHM, van Vroonhoven Th, Gebbink MFBG, **Voest EE**. Continuous administration of angiostatin inhibits accelerated growth of liver metastases after partial hepatectomy. *Cancer Res* 2000; 60:1761-1765

Reijerkerk A, **Voest EE**, Gebbink MFBG. No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancer. *Eur J Cancer* 2000; 36: 1695-1705

- **1999**

Los M, Zeamari S, Foekens A, Gebbink MFBG, **Voest EE**. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. *Cancer Res* 1999; 59:4440-4445

Bloemendal HJ, Logtenberg T, **Voest EE**. New strategies in anti-vascular cancer therapy. *Eur J Clin Invest* 1999; 29:802-809

Reijneveld JC, Taphoorn MJB, **Voest EE**. A simple mouse model for leptomeningeal metastases and repeated intrathecal therapy. *J Neurooncol* 1999; 42:137-142

- **1998**

Poppas DP, Pavlovich CP, Folkman J, **Voest EE**, Chen X, Luster AD, O'Donnell MA. Intravesical Bacillus Calmette-Guerin (BCG) induces the anti-angiogenic chemokine interferon inducible protein 10. *Urology* 1998; 52:268-275.

Kuiper RAJ, Schellens JHM, Blijham GH, Beijnen JH, **Voest EE**. Clinical research of antiangiogenic therapy. *Pharmacol Res* 1998, 37: 1-16

Bottone AE, **Voest EE**, de Beer EL. Impairment of the actin-myosin interaction in permeabilized cardiac trabeculae after chronic doxorubicin treatment. *Clin Cancer Res* 1998, 4: 1031-1037

Voest EE. Neovascularization: the Achilles heel of tumors ?
Drug Resistance Updates 1998, 1:86-87

- **1997**

Anand-Apte B, Pepper MS, **Voest EE**, Montesano R, Olsen B, Murphy G, Apte SS, Zetter B. Inhibition of angiogenesis and tumor growth by tissue inhibitor of metalloproteinase-3 (TIMP-3). *Invest Ophthalmol Vis Sci*, 1997, 38: 817-823

Bottone AE, de Beer EL, **Voest EE**. Anthracyclines enhance tension development in cardiac muscle by direct interaction with the contractile system. *J Mol Cell Cardiol*, 1997; 29: 1001-1008

Los M, Aarsman CJM, Terpstra L, Wittebol-Post D, Lips CJM, Blijham GH, **Voest EE**. Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease. *Ann Oncol*, 1997; 8: 1015-1022

Punt CJA, **Voest EE**, van Oosterom AT, Backx A, de Mulder PHM, Hecquet B, Lucas C, Gerard B, Bleiberg H. Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cancer. *Br J Cancer* 1997; 76: 1376-1381

- **1996**

Kenyon BM, **Voest EE**, Chen CC, Folkman J, D'Amato RJ. A model of angiogenesis in the mouse cornea. *Invest Ophthalmol Vis Sci* 1996;37:1625-1632

Kuroki M, **Voest EE**, Amano S, Beerepoot LV, Takashima S, Tolentino M, Kim RY, Rohan R, Colby KA, Yeo K-T, Adamis AP. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. *J Clin Invest* 1996; 98:1667-1675

Beerepoort LV, Shima DT, Kuroki M, Yeo K-T, **Voest EE**. Up-regulation of vascular endothelial growth factor production by iron chelators. *Cancer Res* 1996;56:3747-3751

van Acker SABE, Kramer K, **Voest EE**, Grimbergen JA, Zhang J, van der Vijgh WJF, Bast A. Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors. *Cancer Chemother Pharmacol* 1996;38:95-101

Voest EE. Inhibitors of angiogenesis in a clinical perspective. *Anti-Cancer Drugs* 1996; 7:723-727

Los M, Jansen G, Lips CJ, Blijham GH, **Voest EE**. Tissue expression of the von Hippel-Lindau protein. *Lab Invest* 1996;75:231-238

- **1995**

Voest EE, Kenyon BM, O'Reilly MS, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. *J Natl Cancer Inst* 1995;87:581-586

Kanters SDJM, Lammers J-JW, **Voest EE**. Molecular and biological factors in the prognosis of non-small cell lung cancer. *Eur Resp J* 1995; 8:1389-1397

- **1994**

Voest EE, Vreugdenhil G, Marx JJM. Iron chelating agents in non-iron overload conditions. *Ann Int Med* 1994;120:490-499

Voest EE, van Acker SABE, van der Vijgh WJF, van Asbeck BS, and Bast A. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity. *J Mol Cell Cardiol* 1994;26:1179-1185

- **1993**

Voest EE, Rooth H, Neijt JP, van Asbeck BS, Marx JJM. The in vitro response of human tumor cells to desferrioxamine is growth medium dependent. *Cell Prolif* 1993;26:77-88

Voest EE, Neijt JP, Keunen JEE, Nortier JWR, van Asbeck BS, Dekker AW, and Marx JJM. A phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity. *Cancer Chemother Pharmacol* 1993;31:357-362

Voest EE, van Faassen E, Marx JJM. An electron paramagnetic resonance study of the antioxidant properties of the nitroxide free radical TEMPO. *Free Rad Biol Med* 1993;15:589-595

Voest EE, van Faassen E, Neijt JP, Marx JJM, van Asbeck BS. Doxorubicin-mediated free radical generation in intact human tumor cells enhances nitroxide electron paramagnetic resonance absorption intensity decay. *Magnetic Resonance Med* 1993;30:283-288

van Acker SABE, **Voest EE**, Beems DB, Madhuizen HT, de Jong J, Bast A, van der Vijgh JWF. Cardioprotective properties of O-(-hydroxyethyl)-rutosides in doxorubicin-pretreated balb/c mice. *Cancer Res* 1993;53:4603-4607

- **1992**

de Beer EL, Finkle H, **Voest EE**, van Heijst BGV, Schiereck P. Doxorubicin directly interacts with skinned single skeletal muscle fibres. *Eur J Pharmacol* 1992;214:97-100

Voest EE, van Faassen E, van Asbeck BS, Neijt JP, Marx JJM. Increased hydrogen peroxide production in human tumor cells due to a nitroxide free radical. *Biochim Biophys Acta* 1992;1136:113-118

- **1991**

Neijt JP, **Voest EE**. Current issues in ovarian cancer; emphasis on dose intensity analysis of chemotherapy. *Ther Strat Oncol* 1991;3:53-75

Voest EE, van Houwelingen JC, Neijt JP. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log(relative risk)) as main objectives. *Eur J Cancer Clin Oncol* 1989;25:711-720

Published Letters

Marx JJM, Vreugdenhil G, and **Voest EE**. Iron chelating agents are not useful in treating atherosclerosis. *Ann Int Med* 1994;121:384-385

Microvessel density and response to treatment in patients with breast cancer. Blijham GH, **Voest EE**. *Cancer J Sci Am* 1997;3:184-185

National Publications

Modulatie van het cellulaire ijzermetabolisme: een aanwinst voor de behandeling van kanker?
E.E. Voest.

Tijdschrift Nederlandse Vereniging voor Klinische Chemie 1993;18:39-42

Angiogenese als aangrijpingspunt voor kankerbehandeling.

E.E. Voest

Kanker, 11, 18-20, 1995,

Bloedvaten als aangrijpingspunt voor de behandeling van kanker.

E.E. Voest

Notitie voor de Gezondheidsraad, 1998

Tumorangiogenese als doelwit voor kankertherapie.

Kuiper RAJ, Schellens JHM, Beijnen JH, Blijham GH, **Voest EE**.

Pharmaceutisch weekblad 134, 572-577, 1999

Patienten met de ziekte van von Hippel Lindau. Nederlands Tijdschrift voor Geneeskunde, 2000; in druk. Los M, **Voest EE**.

Braam BA, Bluysen HAR, **Voest EE**, Koomans H. Gene-expression analysis using DNA microarrays. Ned Tijdschr Geneeskd. 2002;146:1867-73.

Radema SA, Witteveen PO, Gebbink MBFG, **Voest EE**. Het klinisch perspectief van angiogeneseremmers. Ned Tijdschr Geneeskd 2003, 147:1675-1680

Voest EE. Second round for anti-vascular therapies in fighting cancer. Conceptuur 2003, 36:10-11.

Wicherts DA, de Haas RJ, Borel Rinkes IH, **Voest EE**, van Hillegersberg R. Betere behandeling voor patienten met colorectale levermeta's. Ned Tijdschr Geneeskd 2006;150:345-351.

De Mulder PH, Haanen JB, Sleijffer S, Kruit WH, Gietema JA, Richel DJ, Groenewegen G, Voest EE, van den Eertwegh AJ, Osanto S, Jansen RL, Mulders PF. [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus]. Ned Tijdschr Geneeskd. 2008;152:371-5.

Roel H.P. Wouters, Rhodé M. Bijlsma, Emile E. Voest, Annelien L. Bredenoord Nevenbevindingen van genoom-breed onderzoek in de spreekkamer. Ned Tijdschr Geneeskd. 2018 in press

Book chapters

Nieuwe ontwikkelingen in de behandeling van kanker. EE Voest

"Tumor angiogenesis and microcirculation" Editors: D'Amore PA and **Voest EE**
MDI publishers New York, 2001

Chapter 18

Genetic control of angiogenesis by tumor suppressor genes. M Los and **EE Voest**
307-321

Chapter 29

The prognostic and diagnostic value of circulating angiogenic factors in cancer patients. O Kerckheart and **EE Voest**
487-501

Chapter 34

Antiangiogenic Gene Therapy. JC Reijneveld and **EE Voest**
597-609

IHM Borel Rinkes, JM Vogten, **EE Voest**. Chapter 26: Anti-angiogenic Agents for Liver Tumors.

In: Malignant Liver Tumors, Current and emerging therapies (2nd Ed,2002) PA Clavien, editor.

IHM Borel Rinkes, JM Vogten, **EE Voest**. Chapter 26: Anti-angiogenic Agents for Liver Tumors.
In: Malignant Liver Tumors, Current and emerging therapies (3 rd Ed,2008) PA Clavien, editor

Giles RH, **Voest EE**

Tumor suppressor APC and VHL: gatekeepers of the intestine and kidney

Developmental Biology of Neoplastic Growth, pp151-181

Progress in Molecular and Subcellular Biology

Springer-Verlag, Berlin and New York

Ed. Macieira-Coelho A. 2005